#  @mike98572986 mike mike posts on X about $clpt, $qure, rgx 121, ceo the most. They currently have [-----] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours. ### Engagements: [---] [#](/creator/twitter::1422364980339380240/interactions)  - [--] Week [------] +42% - [--] Month [-------] -19% - [--] Months [-------] +392% - [--] Year [-------] +2,181% ### Mentions: [--] [#](/creator/twitter::1422364980339380240/posts_active)  - [--] Week [--] +23% - [--] Month [--] -40% - [--] Months [---] +274% - [--] Year [---] +2,615% ### Followers: [-----] [#](/creator/twitter::1422364980339380240/followers)  - [--] Week [-----] +0.23% - [--] Month [-----] +3.70% - [--] Months [-----] +141% - [--] Year [-----] +433% ### CreatorRank: [---------] [#](/creator/twitter::1422364980339380240/influencer_rank)  ### Social Influence **Social category influence** [finance](/list/finance) 9.52% [social networks](/list/social-networks) 3.97% [technology brands](/list/technology-brands) 3.97% [countries](/list/countries) 2.38% [travel destinations](/list/travel-destinations) 0.79% **Social topic influence** [$clpt](/topic/$clpt) #2, [$qure](/topic/$qure) #17, [rgx 121](/topic/rgx-121) #1, [ceo](/topic/ceo) 7.14%, [if you](/topic/if-you) 6.35%, [$rgnx](/topic/$rgnx) #22, [all the](/topic/all-the) 6.35%, [the first](/topic/the-first) 4.76%, [we are](/topic/we-are) 4.76%, [$xpel](/topic/$xpel) 4.76% **Top accounts mentioned or mentioned by** [@desertdweller93](/creator/undefined) [@profdollar](/creator/undefined) [@petermantas](/creator/undefined) [@biggercapital](/creator/undefined) [@pythiar](/creator/undefined) [@neurostockdoc](/creator/undefined) [@neurosurgeryosu](/creator/undefined) [@ohiostatemed](/creator/undefined) [@fiercebiotech](/creator/undefined) [@chrisbagmancap](/creator/undefined) [@fnrealist](/creator/undefined) [@marketplunger1](/creator/undefined) [@beachstreetgrp](/creator/undefined) [@amaymd](/creator/undefined) [@se19edy](/creator/undefined) [@osugenetherapy](/creator/undefined) [@russelllonser](/creator/undefined) [@osuwexmed](/creator/undefined) [@osucccjames](/creator/undefined) [@drmakaryfda](/creator/undefined) **Top assets mentioned** [uniQure N.V. (QURE)](/topic/$qure) ### Top Social Posts Top posts by engagements in the last [--] hours "$clpt Clearpoint Neuro $Qure [--] part post a novel I wrote a post a few weeks ago about why Clearpoint is having so much success on their gene therapy programs. This post will explain that at a deeper level with real evidence. I believe a lot of investors understand Clearpoint at a high level but sometimes I feel the real insights are in the weeds. It is a long post but I believe out of any key insight this is the one that tells the story. I believe this is well worth your time if interested in Clearpoint. We are going to step back in time here. The game was completely different in the past" [X Link](https://x.com/mike98572986/status/1939296373364666595) 2025-06-29T12:14Z [----] followers, 29.4K engagements "$clpt big time right here A Study of ASP2246 for People Who Have Movement Problems Caused by Brain Injury After a Stroke Astellas Pharma Inc Intracerebral parenchymal infusion via SmartFlow Neuro cannula. Procedure: Brain surgery Stereotactic brain surgery Study start 2026-02-09 [--] for enrollment @peter_mantas @biggercapital https://www.clinicaltrials.gov/study/NCT07318714 https://www.clinicaltrials.gov/study/NCT07318714" [X Link](https://x.com/mike98572986/status/2009095523215524221) 2026-01-08T02:51Z [----] followers, [----] engagements "@biggercapital Yeah Astellas is no joke they likely saw clearpoints work on AviadoBio and were impressed with what they saw. This is definitely a big program and big partner to have" [X Link](https://x.com/mike98572986/status/2009106380318200173) 2026-01-08T03:34Z [----] followers, [----] engagements "$stpt $qure $clpt Good example on why fda needs to really value the doctors patients and parents real world evidence is a powerful thing. The doctors and parents were shouting from the rooftops that the drug works. Certain fda members were extremely skeptical and willing to pull the plug on ELEVIDYS they should eat a humble piece of pie today and realize they arent always correct. Dont own $Srpt but facts are facts that drug works exactly what parents and doctors were saying. At the end of the day you see enough things you have never seen before that isnt randomness at times you need to get" [X Link](https://x.com/mike98572986/status/2015809035845718220) 2026-01-26T15:28Z [----] followers, [----] engagements "$clpt siren Siren believes this marks the first FDA-cleared IND for an adeno-associated virus (AAV)-based therapy in an oncology indication underscoring the growing potential of gene therapy approaches in cancer. This IND clearance represents a defining moment for Siren as we transition from a preclinical-stage company into the clinic said Nicole K. Paulk PhD Founder CEO and President of Siren Biotechnology. Reaching this milestone reflects years of focused platform development rigorous translational work and close engagement with regulators and it positions us to begin evaluating our" [X Link](https://x.com/mike98572986/status/2016572010793750768) 2026-01-28T18:00Z [----] followers, [---] engagements "$clpt definitely a set back we shall see how it plays out Today we announced a regulatory update on our ultra rare MPS programs. Learn more: https://t.co/bIbEjq6zIf https://t.co/TXaTl6Djnh Today we announced a regulatory update on our ultra rare MPS programs. Learn more: https://t.co/bIbEjq6zIf https://t.co/TXaTl6Djnh" [X Link](https://x.com/mike98572986/status/2016573453407834168) 2026-01-28T18:05Z [----] followers, [----] engagements "Interesting https://cowboystatedaily.com/2026/01/28/wyoming-lawmaker-pushes-stem-cell-freedom-act-challenging-fda/ https://cowboystatedaily.com/2026/01/28/wyoming-lawmaker-pushes-stem-cell-freedom-act-challenging-fda/" [X Link](https://x.com/mike98572986/status/2017069572256649273) 2026-01-30T02:57Z [----] followers, [---] engagements "$qure $clpt a good time to bring awareness to the disease Will Forte Gets Candid About His Family's Health Journey with Huntington's Disease https://youtu.be/7BWWM5jjzjs https://youtu.be/7BWWM5jjzjs" [X Link](https://x.com/mike98572986/status/2017705264770924668) 2026-01-31T21:03Z [----] followers, [----] engagements "The grand challenge he said is getting to the point where our AI models can design a variety of molecules with very specific properties almost like tailor-made medicine for a specific person and disease. Isomorphic is now a key player in an increasingly competitive race to revolutionise drug development with AI. Were developing these new technologies that have huge promise but in the end we need to make sure that these medicines are safe he said. Nothing will be gained by racing through and then putting something on the market that isnt going to help patients. He remains committed to finding" [X Link](https://x.com/mike98572986/status/2018017790691865021) 2026-02-01T17:45Z [----] followers, [---] engagements "$clpt #ClearPoint Neuro is starting [----] strong with a team of over [---] people focused entirely on Neuro. Were excited to keep this momentum going and see what we can achieve together #CLPT https://t.co/twlk9jf0CP #ClearPoint Neuro is starting [----] strong with a team of over [---] people focused entirely on Neuro. Were excited to keep this momentum going and see what we can achieve together #CLPT https://t.co/twlk9jf0CP" [X Link](https://x.com/mike98572986/status/2018449380999848043) 2026-02-02T22:20Z [----] followers, [----] engagements "$clpt Kaleida Health (KH) operates three main facilities in Erie County: Bualo General MedicalCenter/Gates Vascular Institute Millard Fillmore Suburban Hospital and John R. Oishei Childrens Hospital. To meet the needs of the community KH has established a weight management clinic at BGMC for adults and established an Eating Disorder Intensive Outpatient Program for children. Kaleida also oers youth suicide prevention services through connecting youth to mental health care. Additionally Kaleida operates a blood disorder clinic in collaboration with Roswell Park Comprehensive Cancer Center and" [X Link](https://x.com/mike98572986/status/2018760637888049625) 2026-02-03T18:56Z [----] followers, [---] engagements "$clpt The House has passed the bill to extend the rare pediatric disease priority review voucher program to [----]. The bill is now on the Presidents desk to be signed into Law. Amazing news for patients and the industry. https://t.co/5OYsg0wJzI The House has passed the bill to extend the rare pediatric disease priority review voucher program to [----]. The bill is now on the Presidents desk to be signed into Law. Amazing news for patients and the industry. https://t.co/5OYsg0wJzI" [X Link](https://x.com/mike98572986/status/2018797675915936235) 2026-02-03T21:24Z [----] followers, [----] engagements "$clpt Astellas abstract of pre-clinical work for the new stroke program asp2246 The median Cyno.mRS scores for the control low-dose and high-dose ASP2246 groups were [--] [--] and [--] respectively with significant improvement noted in the high-dose group compared to the saline control (p0.05). No ASP2246-related abnormalities were observed in clinical signs food consumption or body weight during the study period. Conclusions: ASP2246 a novel mRNA-LNP drug was able to convert astrocytes into neurons in a cell culture model and improved motor dysfunction in a chronic ischemic stroke cynomolgus monkey" [X Link](https://x.com/mike98572986/status/2018905712060166561) 2026-02-04T04:33Z [----] followers, [----] engagements "$clpt Neurona cirm presentation Anyone that hasnt been following the Neurona program very closely should listen to the presentation from a couple days ago if you have followed my account with all the Neurona updates probably not worth it but if not its a good presentation. https://youtu.be/om5_wIBBG3s https://youtu.be/om5_wIBBG3s" [X Link](https://x.com/mike98572986/status/2019065145809600695) 2026-02-04T15:06Z [----] followers, [----] engagements "$qure $clpt FDA document 2/2 Rare Disease Innovation Hub Goals Goal 1: Further Advance Regulatory Science of Rare Disease Therapies Create and enhance opportunities for consideration of novel endpoints biomarker development and assays innovative trial design real world evidence and statistical methods. Initiate engagement with federal research partners and the broader rare disease research community with the purpose of sharing scientific innovations and enhancing collaboration in regulatory science. https://www.fda.gov/media/185144/downloadattachment" [X Link](https://x.com/mike98572986/status/2019068363121783227) 2026-02-04T15:19Z [----] followers, [----] engagements "$clpt Russell Lonser interview 17:53 talks about gene therapy and real time delivery about the [--] minute mark is where I would stop. Its a new paradigm We are now thinking about how do we scale this technology and techniques https://m.youtube.com/watchv=tVfNVlOBeXM&feature=youtu.be https://m.youtube.com/watchv=tVfNVlOBeXM&feature=youtu.be" [X Link](https://x.com/mike98572986/status/2019151038494978096) 2026-02-04T20:48Z [----] followers, [----] engagements "Thursday Bluerocks program presentation 9:30 est if anyone is available would love to hear if anything interesting was said I will likely will not be able to attend either. $clpt Friday elad Levy [--] est might be the more interesting one. They do a lot with clearpoint https://x.com/bernardbendokmd/status/2019245645782216965s=46&t=4McZ7301H76n6S_RDt-dTw https://www.spark-bih.de/news-events/article/spark-bih-national-gct-webinar-dr-stefan-frank https://x.com/bernardbendokmd/status/2019245645782216965s=46&t=4McZ7301H76n6S_RDt-dTw" [X Link](https://x.com/mike98572986/status/2019289958385872998) 2026-02-05T06:00Z [----] followers, [---] engagements "$clpt Kenai If the brain can once again produce normal levels of dopamine Parkinsonsdiseasemaybe sloweddownandmotor functionrestoredsaidBrian LeeMDPhDaneurosurgeon with Keck Medicineandprincipalinvestigator of the study. We believe thattheseiPSCscanreliablymature into dopamine-producing braincellsandoffer the best chance of jump-starting the brainsdopamineproduction saidXenos Mason MD a neurologist who specializes inParkinsons disease and othermovement disorders with Keck Medicine and co-principal investigator of the study." [X Link](https://x.com/mike98572986/status/2019579991479243248) 2026-02-06T01:12Z [----] followers, [----] engagements "$clpt Irraflow TDC-FIT introduced in June [----] for recurrent or high-risk cSDH combined standard TDC with continuous pressure-controlled urokinase irrigation via a dual-lumen IRRAflow catheter or two single-lumen catheters connected to LiquoGuard [--]. This allowed regulated infusion and drainage to promote fibrinolysis while preventing pressure shifts. The introduction of TDC-FIT in [----] was accompanied by a rapid uptake with this technique representing 3.9% of cases in its first year and increasing to 12.6% in [----] TDC-FIT introduced in June [----] was performed in [--] cases (4.4%) mostly for" [X Link](https://x.com/mike98572986/status/2019990409649484153) 2026-02-07T04:23Z [----] followers, [---] engagements "$qure $clpt Looking forward to this session with Dr. Sung UAB #HD Clinic Director & prominent Principal Investigator in current #clinicaltrials Find out what #HDResearch looks like moving into [----] #Help4HDHIPE2026 #UnmaskingtheTruth Register: https://t.co/oF1oE5XHi3 https://t.co/aSv798vLUk Looking forward to this session with Dr. Sung UAB #HD Clinic Director & prominent Principal Investigator in current #clinicaltrials Find out what #HDResearch looks like moving into [----] #Help4HDHIPE2026 #UnmaskingtheTruth Register: https://t.co/oF1oE5XHi3 https://t.co/aSv798vLUk" [X Link](https://x.com/mike98572986/status/2020337749199659165) 2026-02-08T03:23Z [----] followers, [----] engagements "Very cool article 25-40% of clinical trial costs come from an excessive quality-check process that the FDA itself has recommended against for over a decade. Great piece from a former FDA official on why the whole system is stuck in a "too big to fail" loop. https://t.co/yX4gNVy04k https://t.co/sjbdVhioMF 25-40% of clinical trial costs come from an excessive quality-check process that the FDA itself has recommended against for over a decade. Great piece from a former FDA official on why the whole system is stuck in a "too big to fail" loop. https://t.co/yX4gNVy04k https://t.co/sjbdVhioMF" [X Link](https://x.com/mike98572986/status/2020528120214778194) 2026-02-08T16:00Z [----] followers, [---] engagements "I wouldnt go all in they are in a good position but a lot can go wrong. Just like a lot can also go right. My largest position but I believe so far the biggest risk is something coming out that is better and easier to deliver to the brain. There is definitely stuff out there working on this. I even actually expect it good news is that this industry moves extremely slow and by the time a different delivery method becomes mainstream clearpoint already had some big drugs in commercial. Not to mention clearpoint is on the frontlines so hopefully they continue to innovate and be where the puck is" [X Link](https://x.com/mike98572986/status/2020533955150381168) 2026-02-08T16:23Z [----] followers, [---] engagements "$clpt this article is not about clearpoint but gives you an idea why clearpoint keeps winning a outsized amount of deals when it comes to trying to deliver to the brain. This industry doesnt mess around they like reliability and stuff that has worked. Its not worth the risk to try to get all fancy and just use some random start up for your delivery method. Joe said it best at the Mesa [----] when companies start looking for a company to use to deliver to the brain we are in a pretty unique position the fda knows our cannulas very well when getting your trial set up the fda takes about [--] months" [X Link](https://x.com/mike98572986/status/2020538023050625340) 2026-02-08T16:39Z [----] followers, [----] engagements "$qure $clpt @DesertDweller93 Hear about AMT-130 #ClinicalTrial at #Virtual #HIPE We are pleased to have uniQure - Dr. Venugopa PharmD joining us to discuss current #HDResearch Register for Feb 21st #Help4HDHIPE2026 #UnmaskingtheTruth #HD Click here: https://t.co/oF1oE5X9sv https://t.co/rhDenpxIGO Hear about AMT-130 #ClinicalTrial at #Virtual #HIPE We are pleased to have uniQure - Dr. Venugopa PharmD joining us to discuss current #HDResearch Register for Feb 21st #Help4HDHIPE2026 #UnmaskingtheTruth #HD Click here: https://t.co/oF1oE5X9sv https://t.co/rhDenpxIGO" [X Link](https://x.com/mike98572986/status/2020599497014038778) 2026-02-08T20:43Z [----] followers, [----] engagements "RT @FierceBiotech: After facing a delay and clinical hold Regenxbios Hunter syndrome gene therapy has been rejected by the FDA. Fierce in" [X Link](https://x.com/mike98572986/status/2021065570117091704) 2026-02-10T03:35Z [----] followers, [--] engagements "$clpt Kenai At least [--] patients dosed so far https://empoweredpatientradio.com/stem-cell-therapy-aims-to-rebuild-brain-circuits-in-parkinsons-patients-with-dr-howard-federoff-kenai-therapeutics https://empoweredpatientradio.com/stem-cell-therapy-aims-to-rebuild-brain-circuits-in-parkinsons-patients-with-dr-howard-federoff-kenai-therapeutics" [X Link](https://x.com/mike98572986/status/2021739909518963157) 2026-02-12T00:15Z [----] followers, [---] engagements "$clpt $rgnx RGX-121 "I am highly encouraged by the 12-month pivotal data and continued safety and efficacy profile of RGX-121" said Roberto Giugliani M.D. Ph.D. ProfessorDepartment of Genetics UFRGS Medical Genetics Service HCPAPorto Alegre Brazil."The vast majority of Hunter syndrome patients have no current treatment options to address the neurodevelopmental decline of this disease and are in urgent need of new therapies and a one-time treatment option like RGX-121 could make a meaningful impact on their lives."" [X Link](https://x.com/mike98572986/status/1963980489125220585) 2025-09-05T15:00Z [----] followers, [----] engagements "$clpt program new paper Can-3110 The luck continues with clearpoint The serial samples showed that over time the drug changed the environment inside and around the tumor even though the tumor appeared to be progressing on magnetic resonance imaging (MRI) scans. This may happen because the immune system causes swelling and inflammation which can look like new or enlarging areas of contrast on a scan even when a tumor hasnt grown a phenomenon known as pseudoprogression. If CAN-3110 therapy can reshape the microenvironment and activate the immune system it may improve patient outcomes according" [X Link](https://x.com/mike98572986/status/1976066653004943686) 2025-10-08T23:26Z [----] followers, [----] engagements "A solid find $clpt if not following @Chrisbagmancap highly recommend Basically a $CLPT commercial Not even Day [--] yet. https://t.co/4kCJu9EXVL Basically a $CLPT commercial Not even Day [--] yet. https://t.co/4kCJu9EXVL" [X Link](https://x.com/mike98572986/status/1976373976910921791) 2025-10-09T19:47Z [----] followers, [----] engagements "$xpel Market is still sleeping on Xpel these guys dont care whether we are in a crap car market or a roaring car market they will continue to push forward and gain market share with new products partnerships and territories. Pape is a CEO that you can count on to do the right thing very few companies that you can completely trust leadership this is one of them. https://m.youtube.com/watchv=Ssw4bl9AqK8 https://m.youtube.com/watchv=Ssw4bl9AqK8" [X Link](https://x.com/mike98572986/status/1979564314794320089) 2025-10-18T15:04Z [----] followers, [----] engagements "$clpt ceo of IRRAS USA Will Martin post on LinkedIn Today is an exciting day for all of our IRRAS USA Inc. team members as we announce our company's acquisition by ClearPoint Neuro Inc. As we spent time with the ClearPoint Neuro Inc. team over recent months the strategic fit between the two companies became increasingly clear to me - the drive to bring innovation to those devastated by brain injury stroke or rare disease the passion to help patients and the drive to disrupt the status quo by enabling targeted drug delivery to the brain. Thank you to the employees and investors of IRRAS USA" [X Link](https://x.com/mike98572986/status/1987029539789414647) 2025-11-08T05:28Z [----] followers, [----] engagements "$clpt $rgnx if Rgx [---] gets approved I do wonder if RGX-111 starts getting back into action. New article just hit on a child that was part of Rgx-111. This is part of James Wilsons programs once you get [--] approved it makes all the other programs in a really good spot since they are basically using the same processes. 'He's a little miracle' East Tennessee family raises awareness on the importance of clinical trials Jerrik Johnson was diagnosed with Hurler's syndrome when he was six days old. His parents credit early diagnosis and a clinical trial to his success today. Jerrick was the third of" [X Link](https://x.com/mike98572986/status/2010566668670656577) 2026-01-12T04:17Z [----] followers, [----] engagements "$clpt $rgnx ceo of regenxbio speaking on rgx [---] As I mentioned for the Hunter program we're in the middle of a BLA review now. So I won't speak to a lot of specifics about that but it's a very active review. Hunter I don't think there has been a new treatment in Hunter for [--] years. And so there's a huge unmet need here. We deliver directly to the CNS. And there's roughly [---] patients in the prevalent market per se for the U.S. And on an incident basis it's ultrarare so it's roughly [--] new patients per year. There's been a lot of advance in newborn screening for MPS and we want to come in" [X Link](https://x.com/mike98572986/status/2011596712314580999) 2026-01-15T00:30Z [----] followers, [----] engagements "$par very good write up Posting my thoughts on $PAR AI risk as well as recent scuttlebutt https://t.co/TUYOidQOfT Posting my thoughts on $PAR AI risk as well as recent scuttlebutt https://t.co/TUYOidQOfT" [X Link](https://x.com/mike98572986/status/2018494939299283121) 2026-02-03T01:21Z [----] followers, [----] engagements "$par added again I guess all software is going to zero -)" [X Link](https://x.com/mike98572986/status/2018757452624433350) 2026-02-03T18:44Z [----] followers, [----] engagements "Three patients and then I'll probably read out second half of the year on the first [--] but we'll continue to dose cohort two. We call it cohort two. So we'll dose cohort one cohort two but cohort one will probably read out the second half of the year. And if it's anything great I think this is a very unique little company" [X Link](https://x.com/mike98572986/status/2022115036072960039) 2026-02-13T01:06Z [----] followers, [---] engagements "Minute 12:20 $qure $clpt here was the interview that we couldnt get to work from a couple weeks ago Can working up a sweat in a sauna improve your health Liam Gray and a patient that is part of the amt-130 trial and his experience. This study has shown it is possible to slow down the disease. It was a very very tightly matched population. It is a therapy that can be scaled up. Working on same day procedure in and out same day. The patient doesnt even like blood tests and was willing to do it. Jane Davis who was caring for the patient said once the results were released her workload increased" [X Link](https://x.com/mike98572986/status/2018940329731273205) 2026-02-04T06:50Z [----] followers, [----] engagements "$clpt $rgnx Paul Schmidt on LinkedIn Yesterday FDA froze two Regenxbio gene therapy programs after finding a brain tumor in one child. Here's what the press release doesn't sayand what rare disease families are thinking right now: : One 5-year-old. Treated [--] years ago. Asymptomatic tumor found on routine MRI. Causality undetermined. Meanwhile: [--] other patients on that same therapy. Clean. [--] patients on the sister therapy. Clean. Some dosed nearly [--] years ago. Both programs frozen. Including one that was [--] days from a potential FDA decision. : Hunter syndrome doesn't wait for" [X Link](https://x.com/mike98572986/status/2017093755065757989) 2026-01-30T04:33Z [----] followers, [----] engagements "$clpt aadc Spanish translation special stuff Miracles of Science The daughter of a town in Barcelona has an ultra-rare disease known as childhood Parkinsons that affects only [---] children worldwide. Science is advancing and at times being born again becomes almost a reality. This is the case of Irai a girl from Barcelona who came into the world with a rare disease known as childhood Parkinsons. She couldnt speak couldnt walk and couldnt even hold up her head. She was like a rag doll and could only open and close her eyes her mother recalls on Sense Ficci on 3Cat. Today she runs talks and has" [X Link](https://x.com/mike98572986/status/2022124596162703773) 2026-02-13T01:44Z [----] followers, [----] engagements "$Dcth presentation today didnt see the whole presentation things I heard 4-6 procedures per month for Dr padia [--] procedures so far in about 28-29 patients. First procedure he did was April [--] [--]. Says he is booked for February and March his backlog isnt insane anymore due to more and more centers opening on the West Coast. Seemed to imply they definitely could do more than 4-6 per month but at the end of the day they need room time and that is about what works best for the center right now. Sites are openly rapidly quote https://twitter.com/i/web/status/2022730174039839091" [X Link](https://x.com/mike98572986/status/2022730174039839091) 2026-02-14T17:50Z [----] followers, [---] engagements "$clpt $qure The future is bright- Dr Sung This is what I heard on his presentation full disclosure- this is what I heard Dr Sung started the presentation saying he is going rogue he isnt a damn lawyer and is here to speak his mind. He is balls to the wall and ready to speak. He isnt an employee and ready for to give his opinion. He talked about many programs but I will only be posting here about amt-130 he said his patients have [--] views on the surgery some say they are all in - what is the worse that can happen- I die on the operating table Well I have Huntingtons his other patients say hell" [X Link](https://x.com/mike98572986/status/1964425848150511785) 2025-09-06T20:29Z [----] followers, [----] engagements "$clpt $rgnx conference today about rgx [---] Yeah let Steve speak to the data but it looks absolutely exciting. We love what we see in the one-year data. The genesis of the request from FDA was we filed the modules in a rolling BLA fashion. The last module was the clinical module which contained six months' worth of clinical data. I think when the reviewers looked at it they simply saw that these patients should be out [--] months. Can we see that data We accommodated that request very quickly. Having said that that can generate a major amendment and that allows for a three-month delay in the" [X Link](https://x.com/mike98572986/status/1965147251942244444) 2025-09-08T20:16Z [----] followers, [----] engagements "$clpt Neurona-45 minutes in- Justin Graves speaks about his experience after getting the procedure My life is almost completely back to normal. Was having [--] seizures a month before the procedure. Now it is down to maybe [--] or [--]. Says he can drive and travel again. He is about to start swimming again. https://youtu.be/bhzsU9tMhvYsi=qbJu1xdRKoRC8Aau https://youtu.be/bhzsU9tMhvYsi=qbJu1xdRKoRC8Aau" [X Link](https://x.com/mike98572986/status/1968125978426871929) 2025-09-17T01:32Z [----] followers, [----] engagements "$clpt Askbio Gene therapy brings new hope for those suffering from heart failure Parkinson's we believe that in the beginning of the next decade there is going to be like a tsunami of innovation he said. Vanhove said the potential impact of gene therapy is significant. Of the [----] known genetic disorders about [--] percent still have no treatment. Rare diseases individually are rare but collectively we are talking about [---] million people. The unmet medical need is really high he said. He added that gene therapies using AAV have already shown durable effects lasting up to [--] years in other" [X Link](https://x.com/mike98572986/status/1969789840377237552) 2025-09-21T15:44Z [----] followers, 11.1K engagements "$clpt Bayer ceo- [--] big programs with Bayer This is bold important work. For over [--] years the only treatments for patients with Parkinsons have helped manage symptoms not the disease itself.Were aiming to change that for the first time: to stop or slow the disease in its tracks and even restore functions that patients have lost. A decade ago Bayer didnt have a foothold in cell and gene therapies. Today we are proud to advance the development of these potentially game-changing treatments for Parkinsons a disease that affects more than [--] million people worldwide." [X Link](https://x.com/mike98572986/status/1970250454471962970) 2025-09-22T22:14Z [----] followers, [----] engagements "$clpt $qure The violence starts now congratulations to all investors in the two huge win for the hd community this is big time" [X Link](https://x.com/mike98572986/status/1970809738582802822) 2025-09-24T11:17Z [----] followers, [----] engagements "$clpt $qure When Tabrizi speaks like this who is a conservative person you better stand up and listen It means the decline you would normally expect in one year would take four years after treatment giving patients decades of "good quality life" Prof Sarah Tabrizi told BBC News. No wonder Dr. Sung was acting the way he was acting at the last speaking engagement he was dying to share good news" [X Link](https://x.com/mike98572986/status/1970824298194702396) 2025-09-24T12:15Z [----] followers, [----] engagements "$clpt $qure Sarah Tabriz is a like a little girl tasting ice cream for the first time on the call. She is straight up giddy never heard her talk like this. She is straight up super bullish she is all in" [X Link](https://x.com/mike98572986/status/1970837280035356983) 2025-09-24T13:06Z [----] followers, [----] engagements "$clpt $qure The game changer of all game changers has arrived likely [--] drugs approved for clearpoint by September of next year. The world is waking up today and this Huntingtons news is going to spread all around the globe like wildfire every single person that has a family member with HD is now going to get tested. Hold on for dear life day [--] has truly just begun. Good luck to all out there as I said earlier violence is officially here" [X Link](https://x.com/mike98572986/status/1970850762818523269) 2025-09-24T14:00Z [----] followers, [----] engagements "$clpt $qure What people truly dont realize is what will happen next. A truly big player will either buy out uniqure or do some big partnership deal this will get all the other programs that clearpoint is working with them on to get big money spent on speeding along those trials also. A truly transformational day for clearpoint imo the most important day of all time for them" [X Link](https://x.com/mike98572986/status/1970862228481142887) 2025-09-24T14:45Z [----] followers, 10.4K engagements "$clpt $qure More comments from Sarah Tabrizi We now have a treatment for one of the worlds more terrible diseases. This is absolutely huge. Im really overjoyed. With treatment people would be able to work and live independently for significantly longer Tabrizi said and the dramatic impact of the therapy raises the possibility that it could prevent symptoms occurring if given at an earlier stage. Now I think many more people will come forward for the genetic test because theres a treatment said Tabrizi." [X Link](https://x.com/mike98572986/status/1970928713551446024) 2025-09-24T19:09Z [----] followers, [----] engagements "@FnRealist Rgx [---] should be the next one small indication Bluerock Neurona and Askbio have big programs that are moving along nicely" [X Link](https://x.com/mike98572986/status/1971006225140809951) 2025-09-25T00:17Z [----] followers, [---] engagements "$clpt $qure Dr Wild said the patients who took part in the trial were now stable "in a way I'm not used to seeing in Huntington's disease". Professor Stout said that if the treatment is approved by regulators in Australia it could eventually help people with Huntington's have less severe symptoms. "The kind of approach that we take in different forms of dementia is not so much looking for a cure but if we could slow the disease down enough people can live out their natural life span with a high quality of life" she said. "That's like a cure from the point of view from dementia. "The trick" [X Link](https://x.com/mike98572986/status/1971012617851502773) 2025-09-25T00:43Z [----] followers, [----] engagements "$clpt $qure The Sung has spoken Victor Sung a principal investigator for the trial and a movement disorders neurologist at the University of Alabama at Birmingham who is on the steering committee for uniQure said that last year interim data released on the trial was encouraging but open to critiques. An additional year of follow-up he said has surpassed expectations. He previously thought a [--] percent slowdown in progression would be impressive. Weve been burned so many times in the past with failures so everyone is always skeptical about things Sung said. The new data in his view are some of" [X Link](https://x.com/mike98572986/status/1971033289382400357) 2025-09-25T02:05Z [----] followers, [----] engagements "$clpt Think about the incoming inquiries clearpoint is having right now for hospitals asking to get their products so they can also get ready in the future to be able to do this procedure the sales funnel just became a true lay up" [X Link](https://x.com/mike98572986/status/1971215882371371169) 2025-09-25T14:11Z [----] followers, [----] engagements "$clpt big time- Paul Larson one of the best out there I love this move https://ir.clearpointneuro.com/news-events/press-releases/detail/1136/clearpoint-neuro-announces-the-appointment-of-dr-paul https://ir.clearpointneuro.com/news-events/press-releases/detail/1136/clearpoint-neuro-announces-the-appointment-of-dr-paul" [X Link](https://x.com/anyuser/status/1971306014923477435) 2025-09-25T20:09Z [----] followers, [----] engagements "$clpt $qure Brand new interview from Dr wild about amt [---] he is beyond pumped up. Must listen interview its a good one. Too many things to list off here. The affect from year 2-3 not only is it not wearing off the affect is growing and getting better. Dr wild- I speak for myself and everyone else I have spoken with [--] percent is more than anything we could have dreamed or wished for He cannot believe he is actually saying that this is the real deal this is the first treatment for Huntingtons disease like living in a dream. He cannot believe it." [X Link](https://x.com/mike98572986/status/1971365228429574312) 2025-09-26T00:04Z [----] followers, [----] engagements "$clpt $qure It will be necessary to work on the best ways to make this surgery faster she says. We are already working on this challenge. One patient is a former information technology professional who had to stop work due to his symptoms. About a year after being given the gene therapy he was able to go back to work Wild says. In his [--] years of research Wild says this is the only patient hes seen who could do that. But others who expected to be in a wheelchair by now are still walking. https://www.sciencenews.org/article/huntingtons-slowed-with-gene-therapy" [X Link](https://x.com/mike98572986/status/1971738483866980634) 2025-09-27T00:47Z [----] followers, [----] engagements "$clpt $qure Good thoughts about procedure from Courtney Rice from Acadia Strategy Partners on LinkedIn regarding amt-130 A few thoughts on uniQures fabulous news in Huntingtons disease from yesterday Ive seen speculation around how complex administration for this drug might be. WHERE: Will complexity limit administration to a tiny group of COEsIn the US the Phase I/II took place in [--] centers.Analysts have noted that the skill to place this therapy falls well within the skill set of a board-certified neurosurgeon. Recall deep brain stimulation for Parkinsons requires similar invasiveness so" [X Link](https://x.com/mike98572986/status/1971761655722975495) 2025-09-27T02:19Z [----] followers, [----] engagements "Been getting a lot of dms this week about clearpoint $clpt if you want to know what you need to know this thread is all still true on why things are happening now. I dont know where stock goes near term but this is the crux of the big picture and the main things that an investor fully needs to grasp if they are going to hold long term. $clpt Clearpoint Neuro $Qure [--] part post a novel I wrote a post a few weeks ago about why Clearpoint is having so much success on their gene therapy programs. This post will explain that at a deeper level with real evidence. I believe a lot of investors" [X Link](https://x.com/mike98572986/status/1971781599869259952) 2025-09-27T03:39Z [----] followers, [----] engagements "Recommend Peter is one of the top guys out there easily when it comes to Clearpoint knowledge $clpt Did a podcast with @marketplunger1 post $QURE data to talk about what it means for $QURE and $CLPT. Enjoy Did a podcast with @marketplunger1 post $QURE data to talk about what it means for $QURE and $CLPT. Enjoy" [X Link](https://x.com/mike98572986/status/1971961060912779333) 2025-09-27T15:32Z [----] followers, 11.3K engagements "$clpt $qure Awesome article on what the news means to the Huntingtons community "It is like winning the lottery [--] times over" says Gemma [--]. "I had accepted I would never get to grow old with my husband and that he might never see the kids become adults. That has all changed now." "I must have cried for three hours. Then the kids got home from school and I showed my daughter the BBC story and she burst into tears." "In some ways we are lucky he got past [--] with no signs of it" says Gemma. "His mother died from the disease when she was [--]. And now we have the prospect of a treatment. We have" [X Link](https://x.com/mike98572986/status/1971997364627165233) 2025-09-27T17:56Z [----] followers, [----] engagements "$clpt New clearpoint study dont have access to full article but Here we review the experience of a single surgeon with interventional MRI guided DBS targeting of the VIM in ET patients under general anesthesia in a community setting. Method: We conducted a retrospective chart review of ET patients who underwent DBS under general anesthesia using an MRI-guided ClearPoint surgical technique at Willis-Knighton Health System between [----] and [----] Results: A total of [---] ET patients underwent placement of [---] DBS leads. The 2D Radial Error on the was [----] [----] mm with only [--] leads requiring more" [X Link](https://x.com/mike98572986/status/1972022647556132949) 2025-09-27T19:36Z [----] followers, [----] engagements "$qure $clpt Statement from Katie Jackson ceo of help for HD this community is going to rally around this drug like you have never seen before wouldnt surprise me if FDA actually speeds this one up Katie Jackson CEO of Help [--] HD was asked her initial response to the news today. We wanted to share that response with our community. Katie Jackson: I wanted to share my initial thoughts and feelings and I must admit they may surprise you. I have been an advocate for Huntington's disease for almost [--] years. I vividly remember going to Costco to buy the biggest bag of flash-frozen blueberries I" [X Link](https://x.com/mike98572986/status/1972028773131604442) 2025-09-27T20:01Z [----] followers, 17.6K engagements "$clpt Askbio new presentation on ab [----] for Parkinsons minute [----] about delivery. We realized why GDNF hasnt worked it was due to delivery in the last 20-30 years it was the delivery techniques that were the problem not the gene therapy. That was the problem in all the prior studies. We feel our new strategy is a more effective way to get it to the brain. 9:40 mri guided using a system called Clearpoint this is less invasive than DBS some surgeons say the hole is so small they dont even need to close it. Dont have to shave your head. Only a 2-3 hour procedure. Shows videos of the cannula in" [X Link](https://x.com/mike98572986/status/1972047247425905041) 2025-09-27T21:14Z [----] followers, [----] engagements "$clpt $qure Mum died of Huntingtons. this breakthrough changes everything In a call to investors uniQure estimated the cost would be similar to other gene therapies which can be more than $2m a patient. Wild thinks this would be justifiable. Gene therapies are expensive but treating peoples symptoms and looking after people with HD is very expensive Wild said. Delaying the disease in an 18-year-old so symptoms arrive when they are [---] rather than [--] justifies the expense he added. Sheahan had decided never to get tested unless I was thinking of having children or getting married she said. But" [X Link](https://x.com/mike98572986/status/1972318910092628093) 2025-09-28T15:14Z [----] followers, [----] engagements "$clpt With the recent hire of Paul Larson if Im clearpoint I would hire about 5-7 of the top people in this field that have worked with them for a very long time. I would give them RSUs and get them on board. Im not going to list the [--] but my next hire is Krystof Bankiewicz and Mark Richardson these type of people provide massive long term value. Not only do they continually bring Clearpoint big partnerships but they also allow Clearpoint to be on the cutting edge on what is going on in the field. They should lock them down pay them the value is hard to measure on [--] year timeframes but it is" [X Link](https://x.com/mike98572986/status/1972347902824759508) 2025-09-28T17:09Z [----] followers, [----] engagements "$clpt $qure Some new quotes Wild explained that when the gene that causes Huntingtons (HTT) was first discovered in [----] the technology didnt exist to selectively reduce production of disease-causing programs and a range of therapeutic techniques needed to be developed over time. Wild added: To keep things in perspectiveit could have taken [--] years longer without ever seeing a success like this. In the current trial patients had mild signs or symptoms of the disease. But the disease process is essentially the same from birth to death so lowering the protein before symptoms begin should delay" [X Link](https://x.com/mike98572986/status/1972699050152697910) 2025-09-29T16:24Z [----] followers, [----] engagements "$clpt Been getting some dms about where people should sell clearpoint I truly believe each person has to make their own decisions they also need to decide what they are comfortable with going to sleep at night is important clearpoint like any other investment has true risks unknowns and possible black swans. There are absolutely no guarantees how this all plays out. I personally believe over time Bluerock Neurona and Askbio have a good chance of making it all the way. I feel the most confident in Neuronas program. Any one of these approvals would be astronomical these arent happening near" [X Link](https://x.com/anyuser/status/1973052444650451452) 2025-09-30T15:48Z [----] followers, [----] engagements "Rgx [---] is Feb [----] for Hunters syndrome small indication but every drug you can get approved adds up and is important from a marketing standpoint of your products. All the big trials are just starting now so you will not hear much about those for awhile that doesnt mean you might not hear more about prior cohorts/phases though which is always useful information meaning those companies arent required to report how those are going but you have a good chance of hearing about them imo. On the big trials you might get a safety press release but you arent going to get much in [----] its too early." [X Link](https://x.com/mike98572986/status/1973065236342276105) 2025-09-30T16:39Z [----] followers, [---] engagements "$clpt Bluerock Neurona possibly some real catalysts upcoming Shout out to @BeachStreetGrp for reminding me that Bluerock might post the [--] months results in the prior trial they posted [--] months late September [----]. They are under no obligation to do so we shall see if they do. This would be on the prior trial and not phase [--]. Neurona usually posts an update in December. That could be a very good one. This would be on the prior trial and not the phase [--]. A lot of amt-130 news in the upcoming months. Q4 readout for Can-3110 not expecting anything here but it is a read out. Rgx [---] by Feb 2026" [X Link](https://x.com/mike98572986/status/1973284360691572766) 2025-10-01T07:10Z [----] followers, [----] engagements "$clpt $qure More comments from Victor Sung I cried with every single patient Sung says. It just was this crazy feeling that for the patients and families almost cant feel real. Weve had so many failures and theres been a lot of heartbreak over many years in this community Sung says. So to have something that at least really appears to be having an impact is really significant. This is a community that has been waiting for so long for some kind of breakthrough says Rachel Harding a toxicologist at the University of Toronto who helps develop therapies that target the cause of Huntingtons" [X Link](https://x.com/mike98572986/status/1973439573066915913) 2025-10-01T17:27Z [----] followers, 12.6K engagements "$clpt This is really smart and makes more sense on what Joe was talking about on the last call. Our partners are telling us they would like all the procedures to be the same the same workflow and products. With this it allows that to be more of a possible reality not to mention this gives them a good chance of speeding up the time of the procedures which is extremely important in a future world where you will run up on capacity constraint situations if multiple gene therapies get approved over time." [X Link](https://x.com/mike98572986/status/1973504209183195247) 2025-10-01T21:44Z [----] followers, [----] engagements "$clpt $qure Neuroscientist hails news One of New Zealands leading brain research scientists Sir Richard Faull told a Cambridge audience last week that he was over the moon at news of a breakthrough in the treatment of Huntingtons disease. Speaking to over [---] Cambridge U3A members he said news that international researchers had discovered a new gene therapy that slows the diseases progress by [--] per cent was a dream come true. The fact that it is working is incredible. This provides scientific hope for the future not only for Huntingtons but also for other brain diseases caused by genes." [X Link](https://x.com/mike98572986/status/1973691128768835699) 2025-10-02T10:06Z [----] followers, [----] engagements "$clpt CEO of Bluerock doing a presentation in [--] days https://www.linkedin.com/posts/sethettenberg_cgmesa25-activity-7379501053668458496-5_GL https://www.linkedin.com/posts/sethettenberg_cgmesa25-activity-7379501053668458496-5_GL" [X Link](https://x.com/mike98572986/status/1974137524055621663) 2025-10-03T15:40Z [----] followers, [----] engagements "$clpt $qure New presentation from Sarah Tabrizi minute [-----] talks about uniqure procedure does say it is very complex they are getting it down to [--] hours and working on it. Working on shorter protocols. For children they can do it in 3-5 hours. Hour [--] seconds talks about exon1 and why uniqure amt-130 is doing so well. @DesertDweller93 @Prof_Dollar @peter_mantas @PythiaR @biggercapital https://m.youtube.com/watchv=cXsrYM2Fq7g&pp=0gcJCRsBo7VqN5tD https://m.youtube.com/watchv=cXsrYM2Fq7g&pp=0gcJCRsBo7VqN5tD" [X Link](https://x.com/mike98572986/status/1974151998682562574) 2025-10-03T16:38Z [----] followers, 10.3K engagements "$clpt Heck of a couple weeks here guys some people dont ever get these type of runs in a lifetime so truly take some time and be grateful. I tip my hat to Joe and the clearpoint team they did all the hard work we just got on the ride did the work and held on during the tough times. To the outside world clearpoints run looks like an overnight success but they have been working on this for decades it has just come to light now. No idea what next week brings they could raise could drop [--] percent for all I know but enjoy the weekend and congratulations to everyone. Stay humble because anything" [X Link](https://x.com/mike98572986/status/1974202771990892636) 2025-10-03T19:59Z [----] followers, [----] engagements "Clippy is on fire today $clpt It is a very true statement and Joe and their partners are well aware of this subject we dont know all the details of these contracts but I can guarantee you Clearpoint is in a favorable position in these discussions Not to mention without our cannula they cant even do the procedure the pricing power is definitely real you cant abuse it but you have it and it will be good. This is one area that a lot of investors truly arent understanding enough we are locked in you cannot do this procedure without the cannula you have insane pricing power. The cannula is built" [X Link](https://x.com/mike98572986/status/1974546347140489294) 2025-10-04T18:45Z [----] followers, [----] engagements "$clpt You also have to remember clearpoint will be getting paid by the commercial partner they arent going to need to wait for insurance to pay out. If a commercial partner also decides to make long term deals with insurance companies to cover more procedures and get paid out over years that will not be happening with clearpoint you would get the full payment of the procedure. Im not saying amt-130 will need or have a performance type of pay out with insurance companies but it is something to think about with other products down the road" [X Link](https://x.com/mike98572986/status/1974548045015797839) 2025-10-04T18:51Z [----] followers, [----] engagements "$qure $clpt Huntingtons Facebook group [---] votes [--] percent yes on the question If a treatment for Huntingtons disease required brain surgery would you be willing to undergo it" [X Link](https://x.com/mike98572986/status/1974683885100548409) 2025-10-05T03:51Z [----] followers, [----] engagements "$clpt Bluerock [--] yr results https://www.biospace.com/press-releases/bluerock-therapeutics-reports-positive-36-month-results-from-phase-i-trial-of-bemdaneprocel-for-treating-parkinsons-disease https://www.biospace.com/press-releases/bluerock-therapeutics-reports-positive-36-month-results-from-phase-i-trial-of-bemdaneprocel-for-treating-parkinsons-disease" [X Link](https://x.com/anyuser/status/1975598248225357893) 2025-10-07T16:25Z [----] followers, [----] engagements "$clpt Neurona Lets go https://www.neuronatherapeutics.com/news/press-releases/100725/ https://www.neuronatherapeutics.com/news/press-releases/100725/" [X Link](https://x.com/anyuser/status/1975687620253667395) 2025-10-07T22:20Z [----] followers, 10.2K engagements "$clpt $CLSB laser and litt Additional comments regarding the malignant brain tumor study We are very pleased that the neurosurgeons who conducted the study found our system for neuro LITT procedures to be easy to use and that it performed very well. And even if this is a small study its very satisfying to see that the results are this good commented Dan J. Mogren CEO of CLS. For patients with glioblastoma having a minimally invasive option instead of open surgery is an important step forward. This may also provide new treatment options for many inoperable patients. Its less demanding for" [X Link](https://x.com/anyuser/status/1975910745109061907) 2025-10-08T13:06Z [----] followers, [----] engagements "So in the past James Wilson had a presentation where he had pretty much everything they were working on and said they were using the same methods for all the programs in the presentation they had rgx [---] and RGX-111 which are programs that use clearpoint these programs came out of Penn clearpoint has a very close and long relationship with them. There isnt a [---] percent confirmation but it has a high probability https://twitter.com/i/web/status/1976572428613747180 https://twitter.com/i/web/status/1976572428613747180" [X Link](https://x.com/mike98572986/status/1976572428613747180) 2025-10-10T08:56Z [----] followers, [---] engagements "$qure $clpt No wonder Sung was going so crazy last time he spoke I always thought he had only [--] patients under his care. He was seeing it in real time and couldnt say a word. Will be interesting to hear what he says this Sunday now that he can speak. Seven of the [--] high-dose participants were treated at UAB where neurologist Dr. Victor Sung director of the Division of Movement Disorders and the UAB Huntingtons Disease Clinic called the results a huge step toward changing the course of a disease long considered untreatable. There recent procedures are only taking in the 8-10 hour range" [X Link](https://x.com/mike98572986/status/1976797912777867462) 2025-10-10T23:52Z [----] followers, [----] engagements "$clpt $CLSB laser and litt If Im clearpoint I hire 1-2 more sales people for litt every day Im seeing articles of centers or hospitals posting about their 1st litt procedure completed. Litt seems to be going mainstream right about now. You got [--] players in the competition lots of studies in the last year and continues to be used for more and more things over time. I would get aggressive with going after it. It is clearly an avenue with a lot of open space. They got a lot of important things going on right now but this seems like an easy area to really go after" [X Link](https://x.com/anyuser/status/1977068042275504562) 2025-10-11T17:45Z [----] followers, [----] engagements "$qure $clpt Victor Sung He notes that following the recent uniQure news his clinic has received more than [--] calls a day from people wanting to learn more. Hes excited about whats next after this landmark study. https://en.hdbuzz.net/huntingtons-disease-clinical-research-congress-2025-day-1/ https://en.hdbuzz.net/huntingtons-disease-clinical-research-congress-2025-day-1/" [X Link](https://x.com/mike98572986/status/1978240373274107932) 2025-10-14T23:23Z [----] followers, [----] engagements "$Clpt basically a commercial for clearpoint We love to see it https://youtu.be/_xfo2zI6QEosi=7ql2GUZ2eqYIqrAZ https://youtu.be/_xfo2zI6QEosi=7ql2GUZ2eqYIqrAZ" [X Link](https://x.com/anyuser/status/1978293340123676897) 2025-10-15T02:54Z [----] followers, [----] engagements "Nice find $clpt $CLSB laser and litt English translation of the important parts as long as the translation is correct heh Hard-to-reach tumors The study shows that we can now successfully treat patients with hard-to-reach brain tumors. Previously we have not been able to do more for these patients because it entailed too great risks with operating in the traditional way says Peter Siesj chief physician in neurosurgery at Skne University Hospital adjunct professor at Lund University and the person responsible for the study. Faster recovery The alternative is traditional open surgery but with" [X Link](https://x.com/anyuser/status/1978784544829641064) 2025-10-16T11:26Z [----] followers, [----] engagements "$twst Is a good example of analysts giving the market a good set up if you read conference calls [--] percent of the questions evolve around a [--] million dollar contract on a company in the [---] million dollar range of revenues. They spend the majority of their time thinking about whether some irrelevant detail is going to hit in q4 or early next year. These details only matter if all you care about is what the next quarters numbers are going to look like. There is so much more to actually ask questions on that actually will give you insight on whether the company is going to be kicking ass in" [X Link](https://x.com/mike98572986/status/1980656607697703388) 2025-10-21T15:25Z [----] followers, [----] engagements "$clpt Neurona presentation Nov [----] Sharona Ben-Haim goes over what they saw in pre-clinical work and now in humans. If you thought amt130 was a money trial this is on a whole different level. Highly recommend this presentation. There is a reason why @NeuroStockDoc is so bullish on this program. First time we are seeing these type of seizure freedom results without having to actually destroy the underlying tissue that we are treating. We are seeing significant gains in verbal memory visual memory and most importantly quality of life. This could potentially give us an avenue to treat patients" [X Link](https://x.com/mike98572986/status/1980956490333880640) 2025-10-22T11:16Z [----] followers, [----] engagements "$clpt $qure New Victor Sung interview This is impressive because NfL usually only goes up with time in a neurodegenerative disease said study co-author Victor Sung Whats your take on the results Dr. Sung: Comparing the high dose AMT-130 treated patients against a matched control group that comes from an external observational study called Enroll-HD the results on both of the above endpoints were very statistically significant. The caveat is that the number of treated patients was very small so it is hard to say definitively that this will translate to a larger population but the effect size" [X Link](https://x.com/mike98572986/status/1981002567443505177) 2025-10-22T14:19Z [----] followers, 12.8K engagements "$clpt The trajectory of progress is going to be exponential. Accelerated time scales with trials in space is going to speed up learnings very quickly especially in Neuro degenerative diseases where it can take awhile to see changes. Make it an amazing environment. Can compress the time scale. We dont have to wait for a generation to see the results. Interview with Alexander A. Khalessi UC San Diego chair of the Department of Neurological Surgery he doesnt use the word Clearpoint but these guys are super long term partners with them and the wording is definitely talking about Clearpoint. Its" [X Link](https://x.com/mike98572986/status/1981184110044598760) 2025-10-23T02:21Z [----] followers, [----] engagements "FDAs New Cell and Gene Therapy Guidances Finally Go a Click Further to Game Changing $clpt $qure Perhaps the biggest change the new guidance offers for makers of cell and gene therapies is the possibility of self-controlled trials where a patients baseline before treatment can be used as a kind of control for the trial as opposed to a placebo. The draft recommendations which are split into three areas also describe the possibility of externally controlled studiesthose that use historical or real-world data from patients who did not receive the drug as a comparison rather than (or on top of) a" [X Link](https://x.com/mike98572986/status/1981506245640278371) 2025-10-23T23:41Z [----] followers, [----] engagements "$clpt highly likely clearpoint is involved here Elder and Lonser to the brain= high probability Here is what the presentation covered Gene Therapy in Alzheimer's Disease: Analysis of Real-time Magnetic Resonance Imaging of Multi-site Direct Convective Delivery in a First-in-Human Phase I Clinical Trial Brad Elder MD Introduction The current paradigm for gene therapy direct brain delivery for degenerative neurologic disorders uses CED monitored with real time MR-imaging to optimize target coverage. Gene therapy CED to the EC in AD has not been previously described. Objectives To characterize" [X Link](https://x.com/mike98572986/status/1981784568572301352) 2025-10-24T18:07Z [----] followers, [----] engagements "$clpt $qure ed wild throwing fire to naysayers highly recommend The answer Cristina advises is modelling. We can offer a simulated example that if a drug halted progression completely most likely people would only recognize it after [--] or [--] years. That is why in Alzheimers disease people are converting trial results into time saved. A 27% change in AD equals [--] months saved. We need to do these calculations as well for the Uniqure data. A thought experiment extrapolating from the data we already have Lets follow Cristinas suggestion of trying to model time lost and time reclaimed. The average" [X Link](https://x.com/mike98572986/status/1982517026452385971) 2025-10-26T18:37Z [----] followers, 15.9K engagements "$qure $clpt Most excited about the nfl results says his patients doing a [--] hour surgery from his experience are going to have no issues with getting this from a willingness perspective. Conversation is on amt-130. Goes over some of the limitations of the trial. [---] other Neuro diseases out there that this type of treatment might open up. Interview with Danny Bega MD of Northwestern Medicine Neurology https://breakthroughsforphysicians.nm.org/neurosciences-clinical-podcast-hope-for-huntingtons.html" [X Link](https://x.com/mike98572986/status/1983547126832611756) 2025-10-29T14:51Z [----] followers, 11.4K engagements "$qure $clpt Pedro has spoken amt [---] https://leftfieldinvesting.substack.com/p/amt-130-october-17-1977-to-today https://leftfieldinvesting.substack.com/p/amt-130-october-17-1977-to-today" [X Link](https://x.com/anyuser/status/1983704072147628404) 2025-10-30T01:14Z [----] followers, [----] engagements "$clpt litt Robert Gross MD PhD The ClearPoint system allows neurosurgeons to achieve the highest level of consistent accurate precision of any tool available says Christians surgeon Robert Gross MD PhD Chief of Neurosurgery at RWJUH ClearPoint allows direct visualization of whatever one is attempting to insert into the brain as it gets to its intended target using the power of MRI Dr. Gross says. In addition to enabling laser ablation ClearPoint can be used in other ways such as supporting deep brain stimulation and delivering gene and cell therapies to the brain. Its uses span Parkinsons" [X Link](https://x.com/mike98572986/status/1983881249170358518) 2025-10-30T12:58Z [----] followers, [----] engagements "$clpt new paper Preliminary Outcomes of Central Responsive Neurostimulation for Multifocal Epilepsy in Pediatric Patients The preliminary outcomes suggest a robust response to central neurostimulation in pediatric patients suffering from multifocal DRE with an excellent safety profile. Our preliminary reported results in the largest pediatric series of patients treated with neurostimulation of the CM with real-time direct targeting are encouraging with a clinically significant seizure reduction rate and an excellent safety profile. The observed behavioral and cognitive improvements are" [X Link](https://x.com/anyuser/status/1984484650602131638) 2025-11-01T04:56Z [----] followers, [----] engagements "$xpel Ryan Townsley talking about Xpel Marine people are sleeping on Xpel. This one day is going to be a very fast growing part of their business. https://m.youtube.com/watchv=jSSP1IkssiY&pp=0gcJCR4Bo7VqN5tD https://m.youtube.com/watchv=jSSP1IkssiY&pp=0gcJCR4Bo7VqN5tD" [X Link](https://x.com/mike98572986/status/1984859604002685193) 2025-11-02T05:46Z [----] followers, [----] engagements "$xpel James Melfi PPF Product Manager for XPEL interview talks about the strategy and launch of the [--] Ppf colored films https://m.youtube.com/watchv=v79l8yRZhJI https://m.youtube.com/watchv=v79l8yRZhJI" [X Link](https://x.com/mike98572986/status/1984870818959278571) 2025-11-02T06:30Z [----] followers, [----] engagements "$clpt $qure truly Day 1- The technology is [--] years in the making. The last [--] minutes is why Clearpoint is so important this is another reason why they are really trying to introduce robotics and the same exact procedure flow and products at each sight extremely important stuff here. May [----] presentation from Russell Lonser if you want to know why CED techniques and the newer trials are having success this is a good presentation some real gems in this one goes over brain coverage differences in a highly digestible format. Talks about his pal Kris bankiewicz a lot I had seen the slide" [X Link](https://x.com/mike98572986/status/1985170286996783507) 2025-11-03T02:20Z [----] followers, 28.6K engagements "$clpt $qure If you thought prior organizations caused a storm you havent seen nothing yet hd youth organization page-13k followers I personally believe this decision gets overturned. So many factors here but Im keeping this one short. Just posted on fb from their account The US based organizations are meeting to discuss formalized plans on next steps in advocacy. Stay tuned to more details as we all are working to find a way forward" [X Link](https://x.com/mike98572986/status/1985382034098020793) 2025-11-03T16:22Z [----] followers, [----] engagements "$clpt $qure while we all debate what will or will not happen with amt-130 interesting comments here these were before todays press release Henry I. Miller a physician and molecular biologist is the Glenn Swogger Distinguished Fellow at the Science Literacy Project. A veteran of the NIH and FDA he was the founding director of the FDAs Office of Biotechnology. Two aspects of the AMT-130 study constitute a departure from other gene therapy interventions: (1) the convoluted strategy through which the drug (the modified virus) transforms brain cells and causes them to produce an RNA that disrupts" [X Link](https://x.com/mike98572986/status/1985404981378498607) 2025-11-03T17:53Z [----] followers, [----] engagements "$clpt $qure one thing you do have to consider with this whole amt-130 saga you have Sarah Tabrizi Ed Wild and Victor Sung putting their reputations on the line. These are all very respected people in their fields and have been a part of many failed trials. I dont believe these [--] would be easy to be tricked we as humans can all be tricked and want to believe what we want to believe but Sarah Tabrizi straight up said I wouldnt be putting my reputation on the line if I truly didnt believe in the drug. Again this obviously isnt a guarantee of success but it is an extremely strong data point that" [X Link](https://x.com/mike98572986/status/1985879868547236202) 2025-11-05T01:20Z [----] followers, [----] engagements "$xpel Cash Flows from Operations Cash flows provided by operations were $33.2 million in the third quarter of 2025; highest quarter in our history [----] Outlook The Company expects fourth quarter [----] revenue of approximately $123 - $125 million. XPEL announced that it will increase its investment in manufacturing and supply chain via capital expenditures mergers/acquisitions and/or joint ventures. The Company anticipates investing $75 million to $150 million over the next two years with the goal of increasing gross margin to a range of 52% to 54% and operating margin to the mid to high 20%" [X Link](https://x.com/mike98572986/status/1986069705011147083) 2025-11-05T13:54Z [----] followers, [---] engagements "$xpel cc notes Competitors are having issues Xpel is pushing forward with investments while competitors pulling back. Continue to invest in the core business is the plan. Even with investments still will have excess cash repurchases look very attractive. China integration hit the ground running recently. Colored Ppf roll out- our best product roll out ever. Not only do they think they can take market share but believes that market is going to continue to grow. Early days but quite pleased at first when they decided to get into that the goal was to take market share but now also see it as a" [X Link](https://x.com/mike98572986/status/1986111246878580990) 2025-11-05T16:39Z [----] followers, [----] engagements "$clpt $qure seen some posts lately about some posters saying we dont give a shit about the patients in these trials. I think that is bullshit when you spend a lot of time reading hearing about the history and what these people actually go through and thinking about these diseases it impacts you even if you dont have a family member or friend that has it. That is what a decent human being is. I dont give a damn about some financial loss I would love for someone that doesnt give them the right to try to actually go sit face to face with people that go through this shit and still talk like this." [X Link](https://x.com/mike98572986/status/1986274670614806569) 2025-11-06T03:29Z [----] followers, [----] engagements "$clpt $qure Sarah Tabrizi speaks out on LinkedIn I am saddened by the shift in position taken by the current FDA administration regarding the regulatory pathway for uniQures AMT-130 program. This is disappointing news for Huntingtons disease patients and families - particularly the remarkable individuals who volunteered to participate in this pioneering trial - as well as for the wider HD community. The use of external control cohorts is a well-established and scientifically validated approach in rare disease trials - especially in rare conditions like Huntingtons disease where enrolling" [X Link](https://x.com/mike98572986/status/1986335728792654281) 2025-11-06T07:31Z [----] followers, [----] engagements "$clpt this is very good news Were delighted to share that Chair of @NeurosurgeryOSU and Director of @OSUGeneTherapy Russell Lonser M.D. (@RussellLonser) has been named President-Elect of the American Academy of Neurological Surgery (#AAcNS). #Neurosurgery @OhioStateMed @OSUWexMed @OSUCCC_James https://t.co/cx8p46d3re Were delighted to share that Chair of @NeurosurgeryOSU and Director of @OSUGeneTherapy Russell Lonser M.D. (@RussellLonser) has been named President-Elect of the American Academy of Neurological Surgery (#AAcNS). #Neurosurgery @OhioStateMed @OSUWexMed @OSUCCC_James" [X Link](https://x.com/mike98572986/status/1986430143263633824) 2025-11-06T13:47Z [----] followers, [----] engagements "$Clpt underwhelming quarter no question about that need to look more into the acquisition [----] guide feels conservative but I would guide conservative at this point also until after q4 and closure of acquisition. Wasnt a good quarter mentioned move and capacity constrained but nonetheless facts are facts" [X Link](https://x.com/anyuser/status/1986573803699511623) 2025-11-06T23:17Z [----] followers, [----] engagements "$clpt upcoming stuff Trash quarter [--] sites activated need to pick up that pace. Possible reversal on the decision for amt-130 the next couple of months is going to have a lot of discussion on this one. Dec 5-9 Neurona will release new data Acquisition expected to close in q4 Rgx 121- decision by Feb 8th Guiding to 54-60 million for [--] if acquisition closes before [--] starts. I believe that is a sandbagging guide but if I was Joe it is the type of guide I am making today until closure and end of q4. [--] is the year where they need to execute no real excuses to not have a really strong year" [X Link](https://x.com/mike98572986/status/1986609605984870711) 2025-11-07T01:40Z [----] followers, 22.2K engagements "$clpt $qure if ever there was truly a layup of a situation this was it and the fda completely dropped the ball on this situation. Obviously this wasnt just bad for Uniqure this showed the world that the FDAs word is meaningless how does a company trust anything they say going forward This was a black eye for biotech and a complete self inflicted wound by the FDA. Very embarrassing and a sad situation for people with HD hopefully they get this situation reversed in time for the sake of people living with HD @DrMakaryFDA appreciate many of the new initiatives / efforts at transparency /" [X Link](https://x.com/mike98572986/status/1986784211949478311) 2025-11-07T13:14Z [----] followers, [----] engagements "$clpt rgx [---] cc $RGNX Now to RGX-121 also known as chlamidiginelamparvovec the potential first gene therapy and one-time treatment for MPS II. Our recent FDA interactions regarding the ongoing BLA have been highly productive and we remain confident in RGX-121 approval by early next year. We delivered positive 12-month data to FDA which Steve will discuss in more detail. And the FDA completed inspections of our clinical sites and in-house manufacturing facility with no observations a rare and significant achievement. These developments have further strengthened our confidence in the ongoing" [X Link](https://x.com/mike98572986/status/1987183057376628900) 2025-11-08T15:38Z [----] followers, [----] engagements "$clpt Just listened to the call again felt better about it tbh after hearing the call this time. The main thing I think I missed on the first call was the Biologics and drug delivery team really couldnt do much in the quarter because all their time was on the move to the new facility getting everything set up and making sure the certifications were up and running. They definitely have a lot going on mergers arent easy so that definitely has some more execution risk now. The wording on bidding for the new studies was in the [--] million + range compared to largest historically of [--] million. A" [X Link](https://x.com/mike98572986/status/1987260382499762491) 2025-11-08T20:46Z [----] followers, [----] engagements "$clpt rgx [---] $rgnx conference today Got it. So in the last few minutes I want to touch on the Hunter Syndrome program. The FDA requested some additional information. Where are you in that process right now And do you think that's going to be a major amendment Already has been. So we were asked in our mid-cycle meeting sort of in August timeframe of last year to provide we had provided six-month data on the patients for neurocog development. And by the time we had completed the rolling VLA I think FDA looked at the dosing dates and knew we would have one year's worth of data. So we supplied" [X Link](https://x.com/mike98572986/status/1988026945616126004) 2025-11-10T23:32Z [----] followers, [----] engagements "$clpt rgx [---] $rgnx conference yesterday transcript This is going to be the first gene therapy for Hunter's disease and it's in a market that is completely served by enzyme replacement therapy. Even though there is an enzyme replacement therapy that's presumably in development that could cross the blood brain barrier you have the potential to potentially go in there and disrupt it. Though Denali is sitting at a $3 billion valuation you guys are sitting around a $500 million-$600 million valuation. I guess how should we think about this disconnect number one. And number two how do you think" [X Link](https://x.com/mike98572986/status/1988570293804363889) 2025-11-12T11:31Z [----] followers, [----] engagements "$clpt $qure Tuesday November 18th Zoom meeting That is a lot of experts and KOLs speaking EHDN Platform Meeting in collaboration with HDYO and EHA on uniQure topline results: Unpacking the outcomes so far Since the release of uniQures topline results from the AMT-130 gene therapy trial followed by further updates in recent weeks there has been widespread interest across the Huntingtons disease community. This EHDN Platform Meeting organised in collaboration with HDYO and EHA will bring together leading experts and advocates to unpack what the results tell us so far and what they may mean for" [X Link](https://x.com/mike98572986/status/1989484625346138469) 2025-11-15T00:04Z [----] followers, [----] engagements "$clpt minute [--] same delivery on all programs AS first patient dosed last week. If Rgx [---] gets approved in February makes all these programs a lot more attractive from there https://m.youtube.com/watchv=C3SFUDfDbR4 https://m.youtube.com/watchv=C3SFUDfDbR4" [X Link](https://x.com/mike98572986/status/1990577011010711726) 2025-11-18T00:25Z [----] followers, [----] engagements "$xpel I missed that Alta Fox bought a big position in Xpel they have been in and out on the name over the years but last 13f basically had a tracking position on and now [---] percent of the company. https://d18rn0p25nwr6d.cloudfront.net/CIK-0001767258/0cc296c0-ef4b-43a0-ae31-21cfce95a459.pdf https://d18rn0p25nwr6d.cloudfront.net/CIK-0001767258/0cc296c0-ef4b-43a0-ae31-21cfce95a459.pdf" [X Link](https://x.com/mike98572986/status/1998301357061882327) 2025-12-09T07:59Z [----] followers, [---] engagements "Not really true for all you know amt-130 position could change any day decision on rgx [---] in February (not a game changer but if approved that is [--] drugs past the fda possible BTD for Neurona these are all possible catalysts. The biggest one obviously is Amt-130 if you dont believe a positive conclusion will happen on that I can agree with the statement to a large degree. https://twitter.com/i/web/status/1999875103379837042 https://twitter.com/i/web/status/1999875103379837042" [X Link](https://x.com/mike98572986/status/1999875103379837042) 2025-12-13T16:12Z [----] followers, [---] engagements "If RGX-121 receives approval on February [--] it acts as a "green light" for the entire platform that James Wilson is working on. Especially with the fda specifically calling out platform drugs and the advantages of using pretty much the same exact processes and procedures other than the actual drug. https://twitter.com/i/web/status/2010573518967292025 https://twitter.com/i/web/status/2010573518967292025" [X Link](https://x.com/mike98572986/status/2010573518967292025) 2026-01-12T04:44Z [----] followers, [---] engagements "This one will be good because all of James Wilsons projects are using the same exact formula as rgx [---]. So if it gets approved all those other programs instantly become more valuable. He has been talking about the platform solution for quite awhile. All that really changes is the drug for that specific disease they are going after. He feels if one gets approved it validates the other programs because they can use a lot of the prior work with the fda. https://twitter.com/i/web/status/2013400687523016944 https://twitter.com/i/web/status/2013400687523016944" [X Link](https://x.com/mike98572986/status/2013400687523016944) 2026-01-19T23:58Z [----] followers, [---] engagements "$par held my nose and averaged down today personally I dont like that the ceo was just running around saying he wouldnt use equity not really a fan of someone saying something and instantly doing something different but I cant sit here and say the business is struggling. From a business perspective Im comfortable with how par has been run. I will trust that they felt the asset was worth it. https://twitter.com/i/web/status/2016214983433191433 https://twitter.com/i/web/status/2016214983433191433" [X Link](https://x.com/mike98572986/status/2016214983433191433) 2026-01-27T18:21Z [----] followers, [----] engagements Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing
@mike98572986 mike
mike posts on X about $clpt, $qure, rgx 121, ceo the most. They currently have [-----] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours.
Engagements: [---] #
- [--] Week [------] +42%
- [--] Month [-------] -19%
- [--] Months [-------] +392%
- [--] Year [-------] +2,181%
Mentions: [--] #
- [--] Week [--] +23%
- [--] Month [--] -40%
- [--] Months [---] +274%
- [--] Year [---] +2,615%
Followers: [-----] #
- [--] Week [-----] +0.23%
- [--] Month [-----] +3.70%
- [--] Months [-----] +141%
- [--] Year [-----] +433%
CreatorRank: [---------] #
Social Influence
Social category influence finance 9.52% social networks 3.97% technology brands 3.97% countries 2.38% travel destinations 0.79%
Social topic influence $clpt #2, $qure #17, rgx 121 #1, ceo 7.14%, if you 6.35%, $rgnx #22, all the 6.35%, the first 4.76%, we are 4.76%, $xpel 4.76%
Top accounts mentioned or mentioned by @desertdweller93 @profdollar @petermantas @biggercapital @pythiar @neurostockdoc @neurosurgeryosu @ohiostatemed @fiercebiotech @chrisbagmancap @fnrealist @marketplunger1 @beachstreetgrp @amaymd @se19edy @osugenetherapy @russelllonser @osuwexmed @osucccjames @drmakaryfda
Top assets mentioned uniQure N.V. (QURE)
Top Social Posts
Top posts by engagements in the last [--] hours
"$clpt Clearpoint Neuro $Qure [--] part post a novel I wrote a post a few weeks ago about why Clearpoint is having so much success on their gene therapy programs. This post will explain that at a deeper level with real evidence. I believe a lot of investors understand Clearpoint at a high level but sometimes I feel the real insights are in the weeds. It is a long post but I believe out of any key insight this is the one that tells the story. I believe this is well worth your time if interested in Clearpoint. We are going to step back in time here. The game was completely different in the past"
X Link 2025-06-29T12:14Z [----] followers, 29.4K engagements
"$clpt big time right here A Study of ASP2246 for People Who Have Movement Problems Caused by Brain Injury After a Stroke Astellas Pharma Inc Intracerebral parenchymal infusion via SmartFlow Neuro cannula. Procedure: Brain surgery Stereotactic brain surgery Study start 2026-02-09 [--] for enrollment @peter_mantas @biggercapital https://www.clinicaltrials.gov/study/NCT07318714 https://www.clinicaltrials.gov/study/NCT07318714"
X Link 2026-01-08T02:51Z [----] followers, [----] engagements
"@biggercapital Yeah Astellas is no joke they likely saw clearpoints work on AviadoBio and were impressed with what they saw. This is definitely a big program and big partner to have"
X Link 2026-01-08T03:34Z [----] followers, [----] engagements
"$stpt $qure $clpt Good example on why fda needs to really value the doctors patients and parents real world evidence is a powerful thing. The doctors and parents were shouting from the rooftops that the drug works. Certain fda members were extremely skeptical and willing to pull the plug on ELEVIDYS they should eat a humble piece of pie today and realize they arent always correct. Dont own $Srpt but facts are facts that drug works exactly what parents and doctors were saying. At the end of the day you see enough things you have never seen before that isnt randomness at times you need to get"
X Link 2026-01-26T15:28Z [----] followers, [----] engagements
"$clpt siren Siren believes this marks the first FDA-cleared IND for an adeno-associated virus (AAV)-based therapy in an oncology indication underscoring the growing potential of gene therapy approaches in cancer. This IND clearance represents a defining moment for Siren as we transition from a preclinical-stage company into the clinic said Nicole K. Paulk PhD Founder CEO and President of Siren Biotechnology. Reaching this milestone reflects years of focused platform development rigorous translational work and close engagement with regulators and it positions us to begin evaluating our"
X Link 2026-01-28T18:00Z [----] followers, [---] engagements
"$clpt definitely a set back we shall see how it plays out Today we announced a regulatory update on our ultra rare MPS programs. Learn more: https://t.co/bIbEjq6zIf https://t.co/TXaTl6Djnh Today we announced a regulatory update on our ultra rare MPS programs. Learn more: https://t.co/bIbEjq6zIf https://t.co/TXaTl6Djnh"
X Link 2026-01-28T18:05Z [----] followers, [----] engagements
"Interesting https://cowboystatedaily.com/2026/01/28/wyoming-lawmaker-pushes-stem-cell-freedom-act-challenging-fda/ https://cowboystatedaily.com/2026/01/28/wyoming-lawmaker-pushes-stem-cell-freedom-act-challenging-fda/"
X Link 2026-01-30T02:57Z [----] followers, [---] engagements
"$qure $clpt a good time to bring awareness to the disease Will Forte Gets Candid About His Family's Health Journey with Huntington's Disease https://youtu.be/7BWWM5jjzjs https://youtu.be/7BWWM5jjzjs"
X Link 2026-01-31T21:03Z [----] followers, [----] engagements
"The grand challenge he said is getting to the point where our AI models can design a variety of molecules with very specific properties almost like tailor-made medicine for a specific person and disease. Isomorphic is now a key player in an increasingly competitive race to revolutionise drug development with AI. Were developing these new technologies that have huge promise but in the end we need to make sure that these medicines are safe he said. Nothing will be gained by racing through and then putting something on the market that isnt going to help patients. He remains committed to finding"
X Link 2026-02-01T17:45Z [----] followers, [---] engagements
"$clpt #ClearPoint Neuro is starting [----] strong with a team of over [---] people focused entirely on Neuro. Were excited to keep this momentum going and see what we can achieve together #CLPT https://t.co/twlk9jf0CP #ClearPoint Neuro is starting [----] strong with a team of over [---] people focused entirely on Neuro. Were excited to keep this momentum going and see what we can achieve together #CLPT https://t.co/twlk9jf0CP"
X Link 2026-02-02T22:20Z [----] followers, [----] engagements
"$clpt Kaleida Health (KH) operates three main facilities in Erie County: Bualo General MedicalCenter/Gates Vascular Institute Millard Fillmore Suburban Hospital and John R. Oishei Childrens Hospital. To meet the needs of the community KH has established a weight management clinic at BGMC for adults and established an Eating Disorder Intensive Outpatient Program for children. Kaleida also oers youth suicide prevention services through connecting youth to mental health care. Additionally Kaleida operates a blood disorder clinic in collaboration with Roswell Park Comprehensive Cancer Center and"
X Link 2026-02-03T18:56Z [----] followers, [---] engagements
"$clpt The House has passed the bill to extend the rare pediatric disease priority review voucher program to [----]. The bill is now on the Presidents desk to be signed into Law. Amazing news for patients and the industry. https://t.co/5OYsg0wJzI The House has passed the bill to extend the rare pediatric disease priority review voucher program to [----]. The bill is now on the Presidents desk to be signed into Law. Amazing news for patients and the industry. https://t.co/5OYsg0wJzI"
X Link 2026-02-03T21:24Z [----] followers, [----] engagements
"$clpt Astellas abstract of pre-clinical work for the new stroke program asp2246 The median Cyno.mRS scores for the control low-dose and high-dose ASP2246 groups were [--] [--] and [--] respectively with significant improvement noted in the high-dose group compared to the saline control (p0.05). No ASP2246-related abnormalities were observed in clinical signs food consumption or body weight during the study period. Conclusions: ASP2246 a novel mRNA-LNP drug was able to convert astrocytes into neurons in a cell culture model and improved motor dysfunction in a chronic ischemic stroke cynomolgus monkey"
X Link 2026-02-04T04:33Z [----] followers, [----] engagements
"$clpt Neurona cirm presentation Anyone that hasnt been following the Neurona program very closely should listen to the presentation from a couple days ago if you have followed my account with all the Neurona updates probably not worth it but if not its a good presentation. https://youtu.be/om5_wIBBG3s https://youtu.be/om5_wIBBG3s"
X Link 2026-02-04T15:06Z [----] followers, [----] engagements
"$qure $clpt FDA document 2/2 Rare Disease Innovation Hub Goals Goal 1: Further Advance Regulatory Science of Rare Disease Therapies Create and enhance opportunities for consideration of novel endpoints biomarker development and assays innovative trial design real world evidence and statistical methods. Initiate engagement with federal research partners and the broader rare disease research community with the purpose of sharing scientific innovations and enhancing collaboration in regulatory science. https://www.fda.gov/media/185144/downloadattachment"
X Link 2026-02-04T15:19Z [----] followers, [----] engagements
"$clpt Russell Lonser interview 17:53 talks about gene therapy and real time delivery about the [--] minute mark is where I would stop. Its a new paradigm We are now thinking about how do we scale this technology and techniques https://m.youtube.com/watchv=tVfNVlOBeXM&feature=youtu.be https://m.youtube.com/watchv=tVfNVlOBeXM&feature=youtu.be"
X Link 2026-02-04T20:48Z [----] followers, [----] engagements
"Thursday Bluerocks program presentation 9:30 est if anyone is available would love to hear if anything interesting was said I will likely will not be able to attend either. $clpt Friday elad Levy [--] est might be the more interesting one. They do a lot with clearpoint https://x.com/bernardbendokmd/status/2019245645782216965s=46&t=4McZ7301H76n6S_RDt-dTw https://www.spark-bih.de/news-events/article/spark-bih-national-gct-webinar-dr-stefan-frank https://x.com/bernardbendokmd/status/2019245645782216965s=46&t=4McZ7301H76n6S_RDt-dTw"
X Link 2026-02-05T06:00Z [----] followers, [---] engagements
"$clpt Kenai If the brain can once again produce normal levels of dopamine Parkinsonsdiseasemaybe sloweddownandmotor functionrestoredsaidBrian LeeMDPhDaneurosurgeon with Keck Medicineandprincipalinvestigator of the study. We believe thattheseiPSCscanreliablymature into dopamine-producing braincellsandoffer the best chance of jump-starting the brainsdopamineproduction saidXenos Mason MD a neurologist who specializes inParkinsons disease and othermovement disorders with Keck Medicine and co-principal investigator of the study."
X Link 2026-02-06T01:12Z [----] followers, [----] engagements
"$clpt Irraflow TDC-FIT introduced in June [----] for recurrent or high-risk cSDH combined standard TDC with continuous pressure-controlled urokinase irrigation via a dual-lumen IRRAflow catheter or two single-lumen catheters connected to LiquoGuard [--]. This allowed regulated infusion and drainage to promote fibrinolysis while preventing pressure shifts. The introduction of TDC-FIT in [----] was accompanied by a rapid uptake with this technique representing 3.9% of cases in its first year and increasing to 12.6% in [----] TDC-FIT introduced in June [----] was performed in [--] cases (4.4%) mostly for"
X Link 2026-02-07T04:23Z [----] followers, [---] engagements
"$qure $clpt Looking forward to this session with Dr. Sung UAB #HD Clinic Director & prominent Principal Investigator in current #clinicaltrials Find out what #HDResearch looks like moving into [----] #Help4HDHIPE2026 #UnmaskingtheTruth Register: https://t.co/oF1oE5XHi3 https://t.co/aSv798vLUk Looking forward to this session with Dr. Sung UAB #HD Clinic Director & prominent Principal Investigator in current #clinicaltrials Find out what #HDResearch looks like moving into [----] #Help4HDHIPE2026 #UnmaskingtheTruth Register: https://t.co/oF1oE5XHi3 https://t.co/aSv798vLUk"
X Link 2026-02-08T03:23Z [----] followers, [----] engagements
"Very cool article 25-40% of clinical trial costs come from an excessive quality-check process that the FDA itself has recommended against for over a decade. Great piece from a former FDA official on why the whole system is stuck in a "too big to fail" loop. https://t.co/yX4gNVy04k https://t.co/sjbdVhioMF 25-40% of clinical trial costs come from an excessive quality-check process that the FDA itself has recommended against for over a decade. Great piece from a former FDA official on why the whole system is stuck in a "too big to fail" loop. https://t.co/yX4gNVy04k https://t.co/sjbdVhioMF"
X Link 2026-02-08T16:00Z [----] followers, [---] engagements
"I wouldnt go all in they are in a good position but a lot can go wrong. Just like a lot can also go right. My largest position but I believe so far the biggest risk is something coming out that is better and easier to deliver to the brain. There is definitely stuff out there working on this. I even actually expect it good news is that this industry moves extremely slow and by the time a different delivery method becomes mainstream clearpoint already had some big drugs in commercial. Not to mention clearpoint is on the frontlines so hopefully they continue to innovate and be where the puck is"
X Link 2026-02-08T16:23Z [----] followers, [---] engagements
"$clpt this article is not about clearpoint but gives you an idea why clearpoint keeps winning a outsized amount of deals when it comes to trying to deliver to the brain. This industry doesnt mess around they like reliability and stuff that has worked. Its not worth the risk to try to get all fancy and just use some random start up for your delivery method. Joe said it best at the Mesa [----] when companies start looking for a company to use to deliver to the brain we are in a pretty unique position the fda knows our cannulas very well when getting your trial set up the fda takes about [--] months"
X Link 2026-02-08T16:39Z [----] followers, [----] engagements
"$qure $clpt @DesertDweller93 Hear about AMT-130 #ClinicalTrial at #Virtual #HIPE We are pleased to have uniQure - Dr. Venugopa PharmD joining us to discuss current #HDResearch Register for Feb 21st #Help4HDHIPE2026 #UnmaskingtheTruth #HD Click here: https://t.co/oF1oE5X9sv https://t.co/rhDenpxIGO Hear about AMT-130 #ClinicalTrial at #Virtual #HIPE We are pleased to have uniQure - Dr. Venugopa PharmD joining us to discuss current #HDResearch Register for Feb 21st #Help4HDHIPE2026 #UnmaskingtheTruth #HD Click here: https://t.co/oF1oE5X9sv https://t.co/rhDenpxIGO"
X Link 2026-02-08T20:43Z [----] followers, [----] engagements
"RT @FierceBiotech: After facing a delay and clinical hold Regenxbios Hunter syndrome gene therapy has been rejected by the FDA. Fierce in"
X Link 2026-02-10T03:35Z [----] followers, [--] engagements
"$clpt Kenai At least [--] patients dosed so far https://empoweredpatientradio.com/stem-cell-therapy-aims-to-rebuild-brain-circuits-in-parkinsons-patients-with-dr-howard-federoff-kenai-therapeutics https://empoweredpatientradio.com/stem-cell-therapy-aims-to-rebuild-brain-circuits-in-parkinsons-patients-with-dr-howard-federoff-kenai-therapeutics"
X Link 2026-02-12T00:15Z [----] followers, [---] engagements
"$clpt $rgnx RGX-121 "I am highly encouraged by the 12-month pivotal data and continued safety and efficacy profile of RGX-121" said Roberto Giugliani M.D. Ph.D. ProfessorDepartment of Genetics UFRGS Medical Genetics Service HCPAPorto Alegre Brazil."The vast majority of Hunter syndrome patients have no current treatment options to address the neurodevelopmental decline of this disease and are in urgent need of new therapies and a one-time treatment option like RGX-121 could make a meaningful impact on their lives.""
X Link 2025-09-05T15:00Z [----] followers, [----] engagements
"$clpt program new paper Can-3110 The luck continues with clearpoint The serial samples showed that over time the drug changed the environment inside and around the tumor even though the tumor appeared to be progressing on magnetic resonance imaging (MRI) scans. This may happen because the immune system causes swelling and inflammation which can look like new or enlarging areas of contrast on a scan even when a tumor hasnt grown a phenomenon known as pseudoprogression. If CAN-3110 therapy can reshape the microenvironment and activate the immune system it may improve patient outcomes according"
X Link 2025-10-08T23:26Z [----] followers, [----] engagements
"A solid find $clpt if not following @Chrisbagmancap highly recommend Basically a $CLPT commercial Not even Day [--] yet. https://t.co/4kCJu9EXVL Basically a $CLPT commercial Not even Day [--] yet. https://t.co/4kCJu9EXVL"
X Link 2025-10-09T19:47Z [----] followers, [----] engagements
"$xpel Market is still sleeping on Xpel these guys dont care whether we are in a crap car market or a roaring car market they will continue to push forward and gain market share with new products partnerships and territories. Pape is a CEO that you can count on to do the right thing very few companies that you can completely trust leadership this is one of them. https://m.youtube.com/watchv=Ssw4bl9AqK8 https://m.youtube.com/watchv=Ssw4bl9AqK8"
X Link 2025-10-18T15:04Z [----] followers, [----] engagements
"$clpt ceo of IRRAS USA Will Martin post on LinkedIn Today is an exciting day for all of our IRRAS USA Inc. team members as we announce our company's acquisition by ClearPoint Neuro Inc. As we spent time with the ClearPoint Neuro Inc. team over recent months the strategic fit between the two companies became increasingly clear to me - the drive to bring innovation to those devastated by brain injury stroke or rare disease the passion to help patients and the drive to disrupt the status quo by enabling targeted drug delivery to the brain. Thank you to the employees and investors of IRRAS USA"
X Link 2025-11-08T05:28Z [----] followers, [----] engagements
"$clpt $rgnx if Rgx [---] gets approved I do wonder if RGX-111 starts getting back into action. New article just hit on a child that was part of Rgx-111. This is part of James Wilsons programs once you get [--] approved it makes all the other programs in a really good spot since they are basically using the same processes. 'He's a little miracle' East Tennessee family raises awareness on the importance of clinical trials Jerrik Johnson was diagnosed with Hurler's syndrome when he was six days old. His parents credit early diagnosis and a clinical trial to his success today. Jerrick was the third of"
X Link 2026-01-12T04:17Z [----] followers, [----] engagements
"$clpt $rgnx ceo of regenxbio speaking on rgx [---] As I mentioned for the Hunter program we're in the middle of a BLA review now. So I won't speak to a lot of specifics about that but it's a very active review. Hunter I don't think there has been a new treatment in Hunter for [--] years. And so there's a huge unmet need here. We deliver directly to the CNS. And there's roughly [---] patients in the prevalent market per se for the U.S. And on an incident basis it's ultrarare so it's roughly [--] new patients per year. There's been a lot of advance in newborn screening for MPS and we want to come in"
X Link 2026-01-15T00:30Z [----] followers, [----] engagements
"$par very good write up Posting my thoughts on $PAR AI risk as well as recent scuttlebutt https://t.co/TUYOidQOfT Posting my thoughts on $PAR AI risk as well as recent scuttlebutt https://t.co/TUYOidQOfT"
X Link 2026-02-03T01:21Z [----] followers, [----] engagements
"$par added again I guess all software is going to zero -)"
X Link 2026-02-03T18:44Z [----] followers, [----] engagements
"Three patients and then I'll probably read out second half of the year on the first [--] but we'll continue to dose cohort two. We call it cohort two. So we'll dose cohort one cohort two but cohort one will probably read out the second half of the year. And if it's anything great I think this is a very unique little company"
X Link 2026-02-13T01:06Z [----] followers, [---] engagements
"Minute 12:20 $qure $clpt here was the interview that we couldnt get to work from a couple weeks ago Can working up a sweat in a sauna improve your health Liam Gray and a patient that is part of the amt-130 trial and his experience. This study has shown it is possible to slow down the disease. It was a very very tightly matched population. It is a therapy that can be scaled up. Working on same day procedure in and out same day. The patient doesnt even like blood tests and was willing to do it. Jane Davis who was caring for the patient said once the results were released her workload increased"
X Link 2026-02-04T06:50Z [----] followers, [----] engagements
"$clpt $rgnx Paul Schmidt on LinkedIn Yesterday FDA froze two Regenxbio gene therapy programs after finding a brain tumor in one child. Here's what the press release doesn't sayand what rare disease families are thinking right now: : One 5-year-old. Treated [--] years ago. Asymptomatic tumor found on routine MRI. Causality undetermined. Meanwhile: [--] other patients on that same therapy. Clean. [--] patients on the sister therapy. Clean. Some dosed nearly [--] years ago. Both programs frozen. Including one that was [--] days from a potential FDA decision. : Hunter syndrome doesn't wait for"
X Link 2026-01-30T04:33Z [----] followers, [----] engagements
"$clpt aadc Spanish translation special stuff Miracles of Science The daughter of a town in Barcelona has an ultra-rare disease known as childhood Parkinsons that affects only [---] children worldwide. Science is advancing and at times being born again becomes almost a reality. This is the case of Irai a girl from Barcelona who came into the world with a rare disease known as childhood Parkinsons. She couldnt speak couldnt walk and couldnt even hold up her head. She was like a rag doll and could only open and close her eyes her mother recalls on Sense Ficci on 3Cat. Today she runs talks and has"
X Link 2026-02-13T01:44Z [----] followers, [----] engagements
"$Dcth presentation today didnt see the whole presentation things I heard 4-6 procedures per month for Dr padia [--] procedures so far in about 28-29 patients. First procedure he did was April [--] [--]. Says he is booked for February and March his backlog isnt insane anymore due to more and more centers opening on the West Coast. Seemed to imply they definitely could do more than 4-6 per month but at the end of the day they need room time and that is about what works best for the center right now. Sites are openly rapidly quote https://twitter.com/i/web/status/2022730174039839091"
X Link 2026-02-14T17:50Z [----] followers, [---] engagements
"$clpt $qure The future is bright- Dr Sung This is what I heard on his presentation full disclosure- this is what I heard Dr Sung started the presentation saying he is going rogue he isnt a damn lawyer and is here to speak his mind. He is balls to the wall and ready to speak. He isnt an employee and ready for to give his opinion. He talked about many programs but I will only be posting here about amt-130 he said his patients have [--] views on the surgery some say they are all in - what is the worse that can happen- I die on the operating table Well I have Huntingtons his other patients say hell"
X Link 2025-09-06T20:29Z [----] followers, [----] engagements
"$clpt $rgnx conference today about rgx [---] Yeah let Steve speak to the data but it looks absolutely exciting. We love what we see in the one-year data. The genesis of the request from FDA was we filed the modules in a rolling BLA fashion. The last module was the clinical module which contained six months' worth of clinical data. I think when the reviewers looked at it they simply saw that these patients should be out [--] months. Can we see that data We accommodated that request very quickly. Having said that that can generate a major amendment and that allows for a three-month delay in the"
X Link 2025-09-08T20:16Z [----] followers, [----] engagements
"$clpt Neurona-45 minutes in- Justin Graves speaks about his experience after getting the procedure My life is almost completely back to normal. Was having [--] seizures a month before the procedure. Now it is down to maybe [--] or [--]. Says he can drive and travel again. He is about to start swimming again. https://youtu.be/bhzsU9tMhvYsi=qbJu1xdRKoRC8Aau https://youtu.be/bhzsU9tMhvYsi=qbJu1xdRKoRC8Aau"
X Link 2025-09-17T01:32Z [----] followers, [----] engagements
"$clpt Askbio Gene therapy brings new hope for those suffering from heart failure Parkinson's we believe that in the beginning of the next decade there is going to be like a tsunami of innovation he said. Vanhove said the potential impact of gene therapy is significant. Of the [----] known genetic disorders about [--] percent still have no treatment. Rare diseases individually are rare but collectively we are talking about [---] million people. The unmet medical need is really high he said. He added that gene therapies using AAV have already shown durable effects lasting up to [--] years in other"
X Link 2025-09-21T15:44Z [----] followers, 11.1K engagements
"$clpt Bayer ceo- [--] big programs with Bayer This is bold important work. For over [--] years the only treatments for patients with Parkinsons have helped manage symptoms not the disease itself.Were aiming to change that for the first time: to stop or slow the disease in its tracks and even restore functions that patients have lost. A decade ago Bayer didnt have a foothold in cell and gene therapies. Today we are proud to advance the development of these potentially game-changing treatments for Parkinsons a disease that affects more than [--] million people worldwide."
X Link 2025-09-22T22:14Z [----] followers, [----] engagements
"$clpt $qure The violence starts now congratulations to all investors in the two huge win for the hd community this is big time"
X Link 2025-09-24T11:17Z [----] followers, [----] engagements
"$clpt $qure When Tabrizi speaks like this who is a conservative person you better stand up and listen It means the decline you would normally expect in one year would take four years after treatment giving patients decades of "good quality life" Prof Sarah Tabrizi told BBC News. No wonder Dr. Sung was acting the way he was acting at the last speaking engagement he was dying to share good news"
X Link 2025-09-24T12:15Z [----] followers, [----] engagements
"$clpt $qure Sarah Tabriz is a like a little girl tasting ice cream for the first time on the call. She is straight up giddy never heard her talk like this. She is straight up super bullish she is all in"
X Link 2025-09-24T13:06Z [----] followers, [----] engagements
"$clpt $qure The game changer of all game changers has arrived likely [--] drugs approved for clearpoint by September of next year. The world is waking up today and this Huntingtons news is going to spread all around the globe like wildfire every single person that has a family member with HD is now going to get tested. Hold on for dear life day [--] has truly just begun. Good luck to all out there as I said earlier violence is officially here"
X Link 2025-09-24T14:00Z [----] followers, [----] engagements
"$clpt $qure What people truly dont realize is what will happen next. A truly big player will either buy out uniqure or do some big partnership deal this will get all the other programs that clearpoint is working with them on to get big money spent on speeding along those trials also. A truly transformational day for clearpoint imo the most important day of all time for them"
X Link 2025-09-24T14:45Z [----] followers, 10.4K engagements
"$clpt $qure More comments from Sarah Tabrizi We now have a treatment for one of the worlds more terrible diseases. This is absolutely huge. Im really overjoyed. With treatment people would be able to work and live independently for significantly longer Tabrizi said and the dramatic impact of the therapy raises the possibility that it could prevent symptoms occurring if given at an earlier stage. Now I think many more people will come forward for the genetic test because theres a treatment said Tabrizi."
X Link 2025-09-24T19:09Z [----] followers, [----] engagements
"@FnRealist Rgx [---] should be the next one small indication Bluerock Neurona and Askbio have big programs that are moving along nicely"
X Link 2025-09-25T00:17Z [----] followers, [---] engagements
"$clpt $qure Dr Wild said the patients who took part in the trial were now stable "in a way I'm not used to seeing in Huntington's disease". Professor Stout said that if the treatment is approved by regulators in Australia it could eventually help people with Huntington's have less severe symptoms. "The kind of approach that we take in different forms of dementia is not so much looking for a cure but if we could slow the disease down enough people can live out their natural life span with a high quality of life" she said. "That's like a cure from the point of view from dementia. "The trick"
X Link 2025-09-25T00:43Z [----] followers, [----] engagements
"$clpt $qure The Sung has spoken Victor Sung a principal investigator for the trial and a movement disorders neurologist at the University of Alabama at Birmingham who is on the steering committee for uniQure said that last year interim data released on the trial was encouraging but open to critiques. An additional year of follow-up he said has surpassed expectations. He previously thought a [--] percent slowdown in progression would be impressive. Weve been burned so many times in the past with failures so everyone is always skeptical about things Sung said. The new data in his view are some of"
X Link 2025-09-25T02:05Z [----] followers, [----] engagements
"$clpt Think about the incoming inquiries clearpoint is having right now for hospitals asking to get their products so they can also get ready in the future to be able to do this procedure the sales funnel just became a true lay up"
X Link 2025-09-25T14:11Z [----] followers, [----] engagements
"$clpt big time- Paul Larson one of the best out there I love this move https://ir.clearpointneuro.com/news-events/press-releases/detail/1136/clearpoint-neuro-announces-the-appointment-of-dr-paul https://ir.clearpointneuro.com/news-events/press-releases/detail/1136/clearpoint-neuro-announces-the-appointment-of-dr-paul"
X Link 2025-09-25T20:09Z [----] followers, [----] engagements
"$clpt $qure Brand new interview from Dr wild about amt [---] he is beyond pumped up. Must listen interview its a good one. Too many things to list off here. The affect from year 2-3 not only is it not wearing off the affect is growing and getting better. Dr wild- I speak for myself and everyone else I have spoken with [--] percent is more than anything we could have dreamed or wished for He cannot believe he is actually saying that this is the real deal this is the first treatment for Huntingtons disease like living in a dream. He cannot believe it."
X Link 2025-09-26T00:04Z [----] followers, [----] engagements
"$clpt $qure It will be necessary to work on the best ways to make this surgery faster she says. We are already working on this challenge. One patient is a former information technology professional who had to stop work due to his symptoms. About a year after being given the gene therapy he was able to go back to work Wild says. In his [--] years of research Wild says this is the only patient hes seen who could do that. But others who expected to be in a wheelchair by now are still walking. https://www.sciencenews.org/article/huntingtons-slowed-with-gene-therapy"
X Link 2025-09-27T00:47Z [----] followers, [----] engagements
"$clpt $qure Good thoughts about procedure from Courtney Rice from Acadia Strategy Partners on LinkedIn regarding amt-130 A few thoughts on uniQures fabulous news in Huntingtons disease from yesterday Ive seen speculation around how complex administration for this drug might be. WHERE: Will complexity limit administration to a tiny group of COEsIn the US the Phase I/II took place in [--] centers.Analysts have noted that the skill to place this therapy falls well within the skill set of a board-certified neurosurgeon. Recall deep brain stimulation for Parkinsons requires similar invasiveness so"
X Link 2025-09-27T02:19Z [----] followers, [----] engagements
"Been getting a lot of dms this week about clearpoint $clpt if you want to know what you need to know this thread is all still true on why things are happening now. I dont know where stock goes near term but this is the crux of the big picture and the main things that an investor fully needs to grasp if they are going to hold long term. $clpt Clearpoint Neuro $Qure [--] part post a novel I wrote a post a few weeks ago about why Clearpoint is having so much success on their gene therapy programs. This post will explain that at a deeper level with real evidence. I believe a lot of investors"
X Link 2025-09-27T03:39Z [----] followers, [----] engagements
"Recommend Peter is one of the top guys out there easily when it comes to Clearpoint knowledge $clpt Did a podcast with @marketplunger1 post $QURE data to talk about what it means for $QURE and $CLPT. Enjoy Did a podcast with @marketplunger1 post $QURE data to talk about what it means for $QURE and $CLPT. Enjoy"
X Link 2025-09-27T15:32Z [----] followers, 11.3K engagements
"$clpt $qure Awesome article on what the news means to the Huntingtons community "It is like winning the lottery [--] times over" says Gemma [--]. "I had accepted I would never get to grow old with my husband and that he might never see the kids become adults. That has all changed now." "I must have cried for three hours. Then the kids got home from school and I showed my daughter the BBC story and she burst into tears." "In some ways we are lucky he got past [--] with no signs of it" says Gemma. "His mother died from the disease when she was [--]. And now we have the prospect of a treatment. We have"
X Link 2025-09-27T17:56Z [----] followers, [----] engagements
"$clpt New clearpoint study dont have access to full article but Here we review the experience of a single surgeon with interventional MRI guided DBS targeting of the VIM in ET patients under general anesthesia in a community setting. Method: We conducted a retrospective chart review of ET patients who underwent DBS under general anesthesia using an MRI-guided ClearPoint surgical technique at Willis-Knighton Health System between [----] and [----] Results: A total of [---] ET patients underwent placement of [---] DBS leads. The 2D Radial Error on the was [----] [----] mm with only [--] leads requiring more"
X Link 2025-09-27T19:36Z [----] followers, [----] engagements
"$qure $clpt Statement from Katie Jackson ceo of help for HD this community is going to rally around this drug like you have never seen before wouldnt surprise me if FDA actually speeds this one up Katie Jackson CEO of Help [--] HD was asked her initial response to the news today. We wanted to share that response with our community. Katie Jackson: I wanted to share my initial thoughts and feelings and I must admit they may surprise you. I have been an advocate for Huntington's disease for almost [--] years. I vividly remember going to Costco to buy the biggest bag of flash-frozen blueberries I"
X Link 2025-09-27T20:01Z [----] followers, 17.6K engagements
"$clpt Askbio new presentation on ab [----] for Parkinsons minute [----] about delivery. We realized why GDNF hasnt worked it was due to delivery in the last 20-30 years it was the delivery techniques that were the problem not the gene therapy. That was the problem in all the prior studies. We feel our new strategy is a more effective way to get it to the brain. 9:40 mri guided using a system called Clearpoint this is less invasive than DBS some surgeons say the hole is so small they dont even need to close it. Dont have to shave your head. Only a 2-3 hour procedure. Shows videos of the cannula in"
X Link 2025-09-27T21:14Z [----] followers, [----] engagements
"$clpt $qure Mum died of Huntingtons. this breakthrough changes everything In a call to investors uniQure estimated the cost would be similar to other gene therapies which can be more than $2m a patient. Wild thinks this would be justifiable. Gene therapies are expensive but treating peoples symptoms and looking after people with HD is very expensive Wild said. Delaying the disease in an 18-year-old so symptoms arrive when they are [---] rather than [--] justifies the expense he added. Sheahan had decided never to get tested unless I was thinking of having children or getting married she said. But"
X Link 2025-09-28T15:14Z [----] followers, [----] engagements
"$clpt With the recent hire of Paul Larson if Im clearpoint I would hire about 5-7 of the top people in this field that have worked with them for a very long time. I would give them RSUs and get them on board. Im not going to list the [--] but my next hire is Krystof Bankiewicz and Mark Richardson these type of people provide massive long term value. Not only do they continually bring Clearpoint big partnerships but they also allow Clearpoint to be on the cutting edge on what is going on in the field. They should lock them down pay them the value is hard to measure on [--] year timeframes but it is"
X Link 2025-09-28T17:09Z [----] followers, [----] engagements
"$clpt $qure Some new quotes Wild explained that when the gene that causes Huntingtons (HTT) was first discovered in [----] the technology didnt exist to selectively reduce production of disease-causing programs and a range of therapeutic techniques needed to be developed over time. Wild added: To keep things in perspectiveit could have taken [--] years longer without ever seeing a success like this. In the current trial patients had mild signs or symptoms of the disease. But the disease process is essentially the same from birth to death so lowering the protein before symptoms begin should delay"
X Link 2025-09-29T16:24Z [----] followers, [----] engagements
"$clpt Been getting some dms about where people should sell clearpoint I truly believe each person has to make their own decisions they also need to decide what they are comfortable with going to sleep at night is important clearpoint like any other investment has true risks unknowns and possible black swans. There are absolutely no guarantees how this all plays out. I personally believe over time Bluerock Neurona and Askbio have a good chance of making it all the way. I feel the most confident in Neuronas program. Any one of these approvals would be astronomical these arent happening near"
X Link 2025-09-30T15:48Z [----] followers, [----] engagements
"Rgx [---] is Feb [----] for Hunters syndrome small indication but every drug you can get approved adds up and is important from a marketing standpoint of your products. All the big trials are just starting now so you will not hear much about those for awhile that doesnt mean you might not hear more about prior cohorts/phases though which is always useful information meaning those companies arent required to report how those are going but you have a good chance of hearing about them imo. On the big trials you might get a safety press release but you arent going to get much in [----] its too early."
X Link 2025-09-30T16:39Z [----] followers, [---] engagements
"$clpt Bluerock Neurona possibly some real catalysts upcoming Shout out to @BeachStreetGrp for reminding me that Bluerock might post the [--] months results in the prior trial they posted [--] months late September [----]. They are under no obligation to do so we shall see if they do. This would be on the prior trial and not phase [--]. Neurona usually posts an update in December. That could be a very good one. This would be on the prior trial and not the phase [--]. A lot of amt-130 news in the upcoming months. Q4 readout for Can-3110 not expecting anything here but it is a read out. Rgx [---] by Feb 2026"
X Link 2025-10-01T07:10Z [----] followers, [----] engagements
"$clpt $qure More comments from Victor Sung I cried with every single patient Sung says. It just was this crazy feeling that for the patients and families almost cant feel real. Weve had so many failures and theres been a lot of heartbreak over many years in this community Sung says. So to have something that at least really appears to be having an impact is really significant. This is a community that has been waiting for so long for some kind of breakthrough says Rachel Harding a toxicologist at the University of Toronto who helps develop therapies that target the cause of Huntingtons"
X Link 2025-10-01T17:27Z [----] followers, 12.6K engagements
"$clpt This is really smart and makes more sense on what Joe was talking about on the last call. Our partners are telling us they would like all the procedures to be the same the same workflow and products. With this it allows that to be more of a possible reality not to mention this gives them a good chance of speeding up the time of the procedures which is extremely important in a future world where you will run up on capacity constraint situations if multiple gene therapies get approved over time."
X Link 2025-10-01T21:44Z [----] followers, [----] engagements
"$clpt $qure Neuroscientist hails news One of New Zealands leading brain research scientists Sir Richard Faull told a Cambridge audience last week that he was over the moon at news of a breakthrough in the treatment of Huntingtons disease. Speaking to over [---] Cambridge U3A members he said news that international researchers had discovered a new gene therapy that slows the diseases progress by [--] per cent was a dream come true. The fact that it is working is incredible. This provides scientific hope for the future not only for Huntingtons but also for other brain diseases caused by genes."
X Link 2025-10-02T10:06Z [----] followers, [----] engagements
"$clpt CEO of Bluerock doing a presentation in [--] days https://www.linkedin.com/posts/sethettenberg_cgmesa25-activity-7379501053668458496-5_GL https://www.linkedin.com/posts/sethettenberg_cgmesa25-activity-7379501053668458496-5_GL"
X Link 2025-10-03T15:40Z [----] followers, [----] engagements
"$clpt $qure New presentation from Sarah Tabrizi minute [-----] talks about uniqure procedure does say it is very complex they are getting it down to [--] hours and working on it. Working on shorter protocols. For children they can do it in 3-5 hours. Hour [--] seconds talks about exon1 and why uniqure amt-130 is doing so well. @DesertDweller93 @Prof_Dollar @peter_mantas @PythiaR @biggercapital https://m.youtube.com/watchv=cXsrYM2Fq7g&pp=0gcJCRsBo7VqN5tD https://m.youtube.com/watchv=cXsrYM2Fq7g&pp=0gcJCRsBo7VqN5tD"
X Link 2025-10-03T16:38Z [----] followers, 10.3K engagements
"$clpt Heck of a couple weeks here guys some people dont ever get these type of runs in a lifetime so truly take some time and be grateful. I tip my hat to Joe and the clearpoint team they did all the hard work we just got on the ride did the work and held on during the tough times. To the outside world clearpoints run looks like an overnight success but they have been working on this for decades it has just come to light now. No idea what next week brings they could raise could drop [--] percent for all I know but enjoy the weekend and congratulations to everyone. Stay humble because anything"
X Link 2025-10-03T19:59Z [----] followers, [----] engagements
"Clippy is on fire today $clpt It is a very true statement and Joe and their partners are well aware of this subject we dont know all the details of these contracts but I can guarantee you Clearpoint is in a favorable position in these discussions Not to mention without our cannula they cant even do the procedure the pricing power is definitely real you cant abuse it but you have it and it will be good. This is one area that a lot of investors truly arent understanding enough we are locked in you cannot do this procedure without the cannula you have insane pricing power. The cannula is built"
X Link 2025-10-04T18:45Z [----] followers, [----] engagements
"$clpt You also have to remember clearpoint will be getting paid by the commercial partner they arent going to need to wait for insurance to pay out. If a commercial partner also decides to make long term deals with insurance companies to cover more procedures and get paid out over years that will not be happening with clearpoint you would get the full payment of the procedure. Im not saying amt-130 will need or have a performance type of pay out with insurance companies but it is something to think about with other products down the road"
X Link 2025-10-04T18:51Z [----] followers, [----] engagements
"$qure $clpt Huntingtons Facebook group [---] votes [--] percent yes on the question If a treatment for Huntingtons disease required brain surgery would you be willing to undergo it"
X Link 2025-10-05T03:51Z [----] followers, [----] engagements
"$clpt Bluerock [--] yr results https://www.biospace.com/press-releases/bluerock-therapeutics-reports-positive-36-month-results-from-phase-i-trial-of-bemdaneprocel-for-treating-parkinsons-disease https://www.biospace.com/press-releases/bluerock-therapeutics-reports-positive-36-month-results-from-phase-i-trial-of-bemdaneprocel-for-treating-parkinsons-disease"
X Link 2025-10-07T16:25Z [----] followers, [----] engagements
"$clpt Neurona Lets go https://www.neuronatherapeutics.com/news/press-releases/100725/ https://www.neuronatherapeutics.com/news/press-releases/100725/"
X Link 2025-10-07T22:20Z [----] followers, 10.2K engagements
"$clpt $CLSB laser and litt Additional comments regarding the malignant brain tumor study We are very pleased that the neurosurgeons who conducted the study found our system for neuro LITT procedures to be easy to use and that it performed very well. And even if this is a small study its very satisfying to see that the results are this good commented Dan J. Mogren CEO of CLS. For patients with glioblastoma having a minimally invasive option instead of open surgery is an important step forward. This may also provide new treatment options for many inoperable patients. Its less demanding for"
X Link 2025-10-08T13:06Z [----] followers, [----] engagements
"So in the past James Wilson had a presentation where he had pretty much everything they were working on and said they were using the same methods for all the programs in the presentation they had rgx [---] and RGX-111 which are programs that use clearpoint these programs came out of Penn clearpoint has a very close and long relationship with them. There isnt a [---] percent confirmation but it has a high probability https://twitter.com/i/web/status/1976572428613747180 https://twitter.com/i/web/status/1976572428613747180"
X Link 2025-10-10T08:56Z [----] followers, [---] engagements
"$qure $clpt No wonder Sung was going so crazy last time he spoke I always thought he had only [--] patients under his care. He was seeing it in real time and couldnt say a word. Will be interesting to hear what he says this Sunday now that he can speak. Seven of the [--] high-dose participants were treated at UAB where neurologist Dr. Victor Sung director of the Division of Movement Disorders and the UAB Huntingtons Disease Clinic called the results a huge step toward changing the course of a disease long considered untreatable. There recent procedures are only taking in the 8-10 hour range"
X Link 2025-10-10T23:52Z [----] followers, [----] engagements
"$clpt $CLSB laser and litt If Im clearpoint I hire 1-2 more sales people for litt every day Im seeing articles of centers or hospitals posting about their 1st litt procedure completed. Litt seems to be going mainstream right about now. You got [--] players in the competition lots of studies in the last year and continues to be used for more and more things over time. I would get aggressive with going after it. It is clearly an avenue with a lot of open space. They got a lot of important things going on right now but this seems like an easy area to really go after"
X Link 2025-10-11T17:45Z [----] followers, [----] engagements
"$qure $clpt Victor Sung He notes that following the recent uniQure news his clinic has received more than [--] calls a day from people wanting to learn more. Hes excited about whats next after this landmark study. https://en.hdbuzz.net/huntingtons-disease-clinical-research-congress-2025-day-1/ https://en.hdbuzz.net/huntingtons-disease-clinical-research-congress-2025-day-1/"
X Link 2025-10-14T23:23Z [----] followers, [----] engagements
"$Clpt basically a commercial for clearpoint We love to see it https://youtu.be/_xfo2zI6QEosi=7ql2GUZ2eqYIqrAZ https://youtu.be/_xfo2zI6QEosi=7ql2GUZ2eqYIqrAZ"
X Link 2025-10-15T02:54Z [----] followers, [----] engagements
"Nice find $clpt $CLSB laser and litt English translation of the important parts as long as the translation is correct heh Hard-to-reach tumors The study shows that we can now successfully treat patients with hard-to-reach brain tumors. Previously we have not been able to do more for these patients because it entailed too great risks with operating in the traditional way says Peter Siesj chief physician in neurosurgery at Skne University Hospital adjunct professor at Lund University and the person responsible for the study. Faster recovery The alternative is traditional open surgery but with"
X Link 2025-10-16T11:26Z [----] followers, [----] engagements
"$twst Is a good example of analysts giving the market a good set up if you read conference calls [--] percent of the questions evolve around a [--] million dollar contract on a company in the [---] million dollar range of revenues. They spend the majority of their time thinking about whether some irrelevant detail is going to hit in q4 or early next year. These details only matter if all you care about is what the next quarters numbers are going to look like. There is so much more to actually ask questions on that actually will give you insight on whether the company is going to be kicking ass in"
X Link 2025-10-21T15:25Z [----] followers, [----] engagements
"$clpt Neurona presentation Nov [----] Sharona Ben-Haim goes over what they saw in pre-clinical work and now in humans. If you thought amt130 was a money trial this is on a whole different level. Highly recommend this presentation. There is a reason why @NeuroStockDoc is so bullish on this program. First time we are seeing these type of seizure freedom results without having to actually destroy the underlying tissue that we are treating. We are seeing significant gains in verbal memory visual memory and most importantly quality of life. This could potentially give us an avenue to treat patients"
X Link 2025-10-22T11:16Z [----] followers, [----] engagements
"$clpt $qure New Victor Sung interview This is impressive because NfL usually only goes up with time in a neurodegenerative disease said study co-author Victor Sung Whats your take on the results Dr. Sung: Comparing the high dose AMT-130 treated patients against a matched control group that comes from an external observational study called Enroll-HD the results on both of the above endpoints were very statistically significant. The caveat is that the number of treated patients was very small so it is hard to say definitively that this will translate to a larger population but the effect size"
X Link 2025-10-22T14:19Z [----] followers, 12.8K engagements
"$clpt The trajectory of progress is going to be exponential. Accelerated time scales with trials in space is going to speed up learnings very quickly especially in Neuro degenerative diseases where it can take awhile to see changes. Make it an amazing environment. Can compress the time scale. We dont have to wait for a generation to see the results. Interview with Alexander A. Khalessi UC San Diego chair of the Department of Neurological Surgery he doesnt use the word Clearpoint but these guys are super long term partners with them and the wording is definitely talking about Clearpoint. Its"
X Link 2025-10-23T02:21Z [----] followers, [----] engagements
"FDAs New Cell and Gene Therapy Guidances Finally Go a Click Further to Game Changing $clpt $qure Perhaps the biggest change the new guidance offers for makers of cell and gene therapies is the possibility of self-controlled trials where a patients baseline before treatment can be used as a kind of control for the trial as opposed to a placebo. The draft recommendations which are split into three areas also describe the possibility of externally controlled studiesthose that use historical or real-world data from patients who did not receive the drug as a comparison rather than (or on top of) a"
X Link 2025-10-23T23:41Z [----] followers, [----] engagements
"$clpt highly likely clearpoint is involved here Elder and Lonser to the brain= high probability Here is what the presentation covered Gene Therapy in Alzheimer's Disease: Analysis of Real-time Magnetic Resonance Imaging of Multi-site Direct Convective Delivery in a First-in-Human Phase I Clinical Trial Brad Elder MD Introduction The current paradigm for gene therapy direct brain delivery for degenerative neurologic disorders uses CED monitored with real time MR-imaging to optimize target coverage. Gene therapy CED to the EC in AD has not been previously described. Objectives To characterize"
X Link 2025-10-24T18:07Z [----] followers, [----] engagements
"$clpt $qure ed wild throwing fire to naysayers highly recommend The answer Cristina advises is modelling. We can offer a simulated example that if a drug halted progression completely most likely people would only recognize it after [--] or [--] years. That is why in Alzheimers disease people are converting trial results into time saved. A 27% change in AD equals [--] months saved. We need to do these calculations as well for the Uniqure data. A thought experiment extrapolating from the data we already have Lets follow Cristinas suggestion of trying to model time lost and time reclaimed. The average"
X Link 2025-10-26T18:37Z [----] followers, 15.9K engagements
"$qure $clpt Most excited about the nfl results says his patients doing a [--] hour surgery from his experience are going to have no issues with getting this from a willingness perspective. Conversation is on amt-130. Goes over some of the limitations of the trial. [---] other Neuro diseases out there that this type of treatment might open up. Interview with Danny Bega MD of Northwestern Medicine Neurology https://breakthroughsforphysicians.nm.org/neurosciences-clinical-podcast-hope-for-huntingtons.html"
X Link 2025-10-29T14:51Z [----] followers, 11.4K engagements
"$qure $clpt Pedro has spoken amt [---] https://leftfieldinvesting.substack.com/p/amt-130-october-17-1977-to-today https://leftfieldinvesting.substack.com/p/amt-130-october-17-1977-to-today"
X Link 2025-10-30T01:14Z [----] followers, [----] engagements
"$clpt litt Robert Gross MD PhD The ClearPoint system allows neurosurgeons to achieve the highest level of consistent accurate precision of any tool available says Christians surgeon Robert Gross MD PhD Chief of Neurosurgery at RWJUH ClearPoint allows direct visualization of whatever one is attempting to insert into the brain as it gets to its intended target using the power of MRI Dr. Gross says. In addition to enabling laser ablation ClearPoint can be used in other ways such as supporting deep brain stimulation and delivering gene and cell therapies to the brain. Its uses span Parkinsons"
X Link 2025-10-30T12:58Z [----] followers, [----] engagements
"$clpt new paper Preliminary Outcomes of Central Responsive Neurostimulation for Multifocal Epilepsy in Pediatric Patients The preliminary outcomes suggest a robust response to central neurostimulation in pediatric patients suffering from multifocal DRE with an excellent safety profile. Our preliminary reported results in the largest pediatric series of patients treated with neurostimulation of the CM with real-time direct targeting are encouraging with a clinically significant seizure reduction rate and an excellent safety profile. The observed behavioral and cognitive improvements are"
X Link 2025-11-01T04:56Z [----] followers, [----] engagements
"$xpel Ryan Townsley talking about Xpel Marine people are sleeping on Xpel. This one day is going to be a very fast growing part of their business. https://m.youtube.com/watchv=jSSP1IkssiY&pp=0gcJCR4Bo7VqN5tD https://m.youtube.com/watchv=jSSP1IkssiY&pp=0gcJCR4Bo7VqN5tD"
X Link 2025-11-02T05:46Z [----] followers, [----] engagements
"$xpel James Melfi PPF Product Manager for XPEL interview talks about the strategy and launch of the [--] Ppf colored films https://m.youtube.com/watchv=v79l8yRZhJI https://m.youtube.com/watchv=v79l8yRZhJI"
X Link 2025-11-02T06:30Z [----] followers, [----] engagements
"$clpt $qure truly Day 1- The technology is [--] years in the making. The last [--] minutes is why Clearpoint is so important this is another reason why they are really trying to introduce robotics and the same exact procedure flow and products at each sight extremely important stuff here. May [----] presentation from Russell Lonser if you want to know why CED techniques and the newer trials are having success this is a good presentation some real gems in this one goes over brain coverage differences in a highly digestible format. Talks about his pal Kris bankiewicz a lot I had seen the slide"
X Link 2025-11-03T02:20Z [----] followers, 28.6K engagements
"$clpt $qure If you thought prior organizations caused a storm you havent seen nothing yet hd youth organization page-13k followers I personally believe this decision gets overturned. So many factors here but Im keeping this one short. Just posted on fb from their account The US based organizations are meeting to discuss formalized plans on next steps in advocacy. Stay tuned to more details as we all are working to find a way forward"
X Link 2025-11-03T16:22Z [----] followers, [----] engagements
"$clpt $qure while we all debate what will or will not happen with amt-130 interesting comments here these were before todays press release Henry I. Miller a physician and molecular biologist is the Glenn Swogger Distinguished Fellow at the Science Literacy Project. A veteran of the NIH and FDA he was the founding director of the FDAs Office of Biotechnology. Two aspects of the AMT-130 study constitute a departure from other gene therapy interventions: (1) the convoluted strategy through which the drug (the modified virus) transforms brain cells and causes them to produce an RNA that disrupts"
X Link 2025-11-03T17:53Z [----] followers, [----] engagements
"$clpt $qure one thing you do have to consider with this whole amt-130 saga you have Sarah Tabrizi Ed Wild and Victor Sung putting their reputations on the line. These are all very respected people in their fields and have been a part of many failed trials. I dont believe these [--] would be easy to be tricked we as humans can all be tricked and want to believe what we want to believe but Sarah Tabrizi straight up said I wouldnt be putting my reputation on the line if I truly didnt believe in the drug. Again this obviously isnt a guarantee of success but it is an extremely strong data point that"
X Link 2025-11-05T01:20Z [----] followers, [----] engagements
"$xpel Cash Flows from Operations Cash flows provided by operations were $33.2 million in the third quarter of 2025; highest quarter in our history [----] Outlook The Company expects fourth quarter [----] revenue of approximately $123 - $125 million. XPEL announced that it will increase its investment in manufacturing and supply chain via capital expenditures mergers/acquisitions and/or joint ventures. The Company anticipates investing $75 million to $150 million over the next two years with the goal of increasing gross margin to a range of 52% to 54% and operating margin to the mid to high 20%"
X Link 2025-11-05T13:54Z [----] followers, [---] engagements
"$xpel cc notes Competitors are having issues Xpel is pushing forward with investments while competitors pulling back. Continue to invest in the core business is the plan. Even with investments still will have excess cash repurchases look very attractive. China integration hit the ground running recently. Colored Ppf roll out- our best product roll out ever. Not only do they think they can take market share but believes that market is going to continue to grow. Early days but quite pleased at first when they decided to get into that the goal was to take market share but now also see it as a"
X Link 2025-11-05T16:39Z [----] followers, [----] engagements
"$clpt $qure seen some posts lately about some posters saying we dont give a shit about the patients in these trials. I think that is bullshit when you spend a lot of time reading hearing about the history and what these people actually go through and thinking about these diseases it impacts you even if you dont have a family member or friend that has it. That is what a decent human being is. I dont give a damn about some financial loss I would love for someone that doesnt give them the right to try to actually go sit face to face with people that go through this shit and still talk like this."
X Link 2025-11-06T03:29Z [----] followers, [----] engagements
"$clpt $qure Sarah Tabrizi speaks out on LinkedIn I am saddened by the shift in position taken by the current FDA administration regarding the regulatory pathway for uniQures AMT-130 program. This is disappointing news for Huntingtons disease patients and families - particularly the remarkable individuals who volunteered to participate in this pioneering trial - as well as for the wider HD community. The use of external control cohorts is a well-established and scientifically validated approach in rare disease trials - especially in rare conditions like Huntingtons disease where enrolling"
X Link 2025-11-06T07:31Z [----] followers, [----] engagements
"$clpt this is very good news Were delighted to share that Chair of @NeurosurgeryOSU and Director of @OSUGeneTherapy Russell Lonser M.D. (@RussellLonser) has been named President-Elect of the American Academy of Neurological Surgery (#AAcNS). #Neurosurgery @OhioStateMed @OSUWexMed @OSUCCC_James https://t.co/cx8p46d3re Were delighted to share that Chair of @NeurosurgeryOSU and Director of @OSUGeneTherapy Russell Lonser M.D. (@RussellLonser) has been named President-Elect of the American Academy of Neurological Surgery (#AAcNS). #Neurosurgery @OhioStateMed @OSUWexMed @OSUCCC_James"
X Link 2025-11-06T13:47Z [----] followers, [----] engagements
"$Clpt underwhelming quarter no question about that need to look more into the acquisition [----] guide feels conservative but I would guide conservative at this point also until after q4 and closure of acquisition. Wasnt a good quarter mentioned move and capacity constrained but nonetheless facts are facts"
X Link 2025-11-06T23:17Z [----] followers, [----] engagements
"$clpt upcoming stuff Trash quarter [--] sites activated need to pick up that pace. Possible reversal on the decision for amt-130 the next couple of months is going to have a lot of discussion on this one. Dec 5-9 Neurona will release new data Acquisition expected to close in q4 Rgx 121- decision by Feb 8th Guiding to 54-60 million for [--] if acquisition closes before [--] starts. I believe that is a sandbagging guide but if I was Joe it is the type of guide I am making today until closure and end of q4. [--] is the year where they need to execute no real excuses to not have a really strong year"
X Link 2025-11-07T01:40Z [----] followers, 22.2K engagements
"$clpt $qure if ever there was truly a layup of a situation this was it and the fda completely dropped the ball on this situation. Obviously this wasnt just bad for Uniqure this showed the world that the FDAs word is meaningless how does a company trust anything they say going forward This was a black eye for biotech and a complete self inflicted wound by the FDA. Very embarrassing and a sad situation for people with HD hopefully they get this situation reversed in time for the sake of people living with HD @DrMakaryFDA appreciate many of the new initiatives / efforts at transparency /"
X Link 2025-11-07T13:14Z [----] followers, [----] engagements
"$clpt rgx [---] cc $RGNX Now to RGX-121 also known as chlamidiginelamparvovec the potential first gene therapy and one-time treatment for MPS II. Our recent FDA interactions regarding the ongoing BLA have been highly productive and we remain confident in RGX-121 approval by early next year. We delivered positive 12-month data to FDA which Steve will discuss in more detail. And the FDA completed inspections of our clinical sites and in-house manufacturing facility with no observations a rare and significant achievement. These developments have further strengthened our confidence in the ongoing"
X Link 2025-11-08T15:38Z [----] followers, [----] engagements
"$clpt Just listened to the call again felt better about it tbh after hearing the call this time. The main thing I think I missed on the first call was the Biologics and drug delivery team really couldnt do much in the quarter because all their time was on the move to the new facility getting everything set up and making sure the certifications were up and running. They definitely have a lot going on mergers arent easy so that definitely has some more execution risk now. The wording on bidding for the new studies was in the [--] million + range compared to largest historically of [--] million. A"
X Link 2025-11-08T20:46Z [----] followers, [----] engagements
"$clpt rgx [---] $rgnx conference today Got it. So in the last few minutes I want to touch on the Hunter Syndrome program. The FDA requested some additional information. Where are you in that process right now And do you think that's going to be a major amendment Already has been. So we were asked in our mid-cycle meeting sort of in August timeframe of last year to provide we had provided six-month data on the patients for neurocog development. And by the time we had completed the rolling VLA I think FDA looked at the dosing dates and knew we would have one year's worth of data. So we supplied"
X Link 2025-11-10T23:32Z [----] followers, [----] engagements
"$clpt rgx [---] $rgnx conference yesterday transcript This is going to be the first gene therapy for Hunter's disease and it's in a market that is completely served by enzyme replacement therapy. Even though there is an enzyme replacement therapy that's presumably in development that could cross the blood brain barrier you have the potential to potentially go in there and disrupt it. Though Denali is sitting at a $3 billion valuation you guys are sitting around a $500 million-$600 million valuation. I guess how should we think about this disconnect number one. And number two how do you think"
X Link 2025-11-12T11:31Z [----] followers, [----] engagements
"$clpt $qure Tuesday November 18th Zoom meeting That is a lot of experts and KOLs speaking EHDN Platform Meeting in collaboration with HDYO and EHA on uniQure topline results: Unpacking the outcomes so far Since the release of uniQures topline results from the AMT-130 gene therapy trial followed by further updates in recent weeks there has been widespread interest across the Huntingtons disease community. This EHDN Platform Meeting organised in collaboration with HDYO and EHA will bring together leading experts and advocates to unpack what the results tell us so far and what they may mean for"
X Link 2025-11-15T00:04Z [----] followers, [----] engagements
"$clpt minute [--] same delivery on all programs AS first patient dosed last week. If Rgx [---] gets approved in February makes all these programs a lot more attractive from there https://m.youtube.com/watchv=C3SFUDfDbR4 https://m.youtube.com/watchv=C3SFUDfDbR4"
X Link 2025-11-18T00:25Z [----] followers, [----] engagements
"$xpel I missed that Alta Fox bought a big position in Xpel they have been in and out on the name over the years but last 13f basically had a tracking position on and now [---] percent of the company. https://d18rn0p25nwr6d.cloudfront.net/CIK-0001767258/0cc296c0-ef4b-43a0-ae31-21cfce95a459.pdf https://d18rn0p25nwr6d.cloudfront.net/CIK-0001767258/0cc296c0-ef4b-43a0-ae31-21cfce95a459.pdf"
X Link 2025-12-09T07:59Z [----] followers, [---] engagements
"Not really true for all you know amt-130 position could change any day decision on rgx [---] in February (not a game changer but if approved that is [--] drugs past the fda possible BTD for Neurona these are all possible catalysts. The biggest one obviously is Amt-130 if you dont believe a positive conclusion will happen on that I can agree with the statement to a large degree. https://twitter.com/i/web/status/1999875103379837042 https://twitter.com/i/web/status/1999875103379837042"
X Link 2025-12-13T16:12Z [----] followers, [---] engagements
"If RGX-121 receives approval on February [--] it acts as a "green light" for the entire platform that James Wilson is working on. Especially with the fda specifically calling out platform drugs and the advantages of using pretty much the same exact processes and procedures other than the actual drug. https://twitter.com/i/web/status/2010573518967292025 https://twitter.com/i/web/status/2010573518967292025"
X Link 2026-01-12T04:44Z [----] followers, [---] engagements
"This one will be good because all of James Wilsons projects are using the same exact formula as rgx [---]. So if it gets approved all those other programs instantly become more valuable. He has been talking about the platform solution for quite awhile. All that really changes is the drug for that specific disease they are going after. He feels if one gets approved it validates the other programs because they can use a lot of the prior work with the fda. https://twitter.com/i/web/status/2013400687523016944 https://twitter.com/i/web/status/2013400687523016944"
X Link 2026-01-19T23:58Z [----] followers, [---] engagements
"$par held my nose and averaged down today personally I dont like that the ceo was just running around saying he wouldnt use equity not really a fan of someone saying something and instantly doing something different but I cant sit here and say the business is struggling. From a business perspective Im comfortable with how par has been run. I will trust that they felt the asset was worth it. https://twitter.com/i/web/status/2016214983433191433 https://twitter.com/i/web/status/2016214983433191433"
X Link 2026-01-27T18:21Z [----] followers, [----] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing